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Abstract	
Glioblastoma	 multiforme	 is	 the	 most	 aggressive	 form	 of	 brain	 cancer	 due	 to	 high	 rates	 of	
reoccurrence.	 	 Although	 >95%	of	 a	 tumor	 can	 be	 removed	with	 surgery,	 the	 invasiveness	 of	
gliomas	 frequently	 leads	 to	 the	 formation	 of	 tumors	 at	 secondary	 sites.	 The	 invasiveness	 of	
gliomas	is	in	part	due	to	their	ability	to	secrete	proteolytic	enzymes,	including	members	of	the	
matrix	 metalloproteinase	 (MMP)	 family,	 that	 are	 involved	 with	 the	 remodeling	 of	 the	
extracellular	matrix.	In	this	study,	MMP-3	expression	and	activity	was	found	to	be	upregulated	in	
C6-13	rat	glioma	cells	that	exogenously	express	the	promigratory	protein	Cx43.	Based	on	these	
findings,	a	panel	of	synthesized	inhibitors	were	proposed	and	benchmarked	against	ilomastat,	a	
known	inhibitor	of	MMP-3.		Binding	ability	of	inhibitors	to	the	MMP-3	active	site	was	performed	
using	in	silico	molecular	docking.	Ilomastat	was	chosen	for	further	activity	studies,	in	which	MMP-
3	was	 significantly	 inhibited.	 Findings	 presented	 in	 this	 thesis	 indicate	 that	MMP-3	 activity	 is	
upregulate	 in	C6-13	 rat	 glioma	cells	 and	can	be	 significantly	 inhibited.	MMP-3	 inhibition	may	
contribute	to	decreasing	invasive	potential	of	glioma	cells.		
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Preface	
My	role	in	this	thesis	was	to	further	investigate	the	activity	of	MMP-3,	design	and	synthesize	
novel	MMP-3	inhibitors,	and	monitor	the	change	MMP-3	activity	upon	inhibition.	The	cell	lines	
used	in	this	thesis	(parental	C6	and	C6-13)	were	provided	by	Dr.	Christian	Naus	at	the	University	
of	British	Columbia.	I	wrote	the	methods	for	the	experiments	I	carried	out,	with	the	exception	
of	the	zymography	protocol	which	was	assisted	by	Emmanuel	Ojefua.	I	used	ImageJ	to	quantify	
Western	blot,	zymography,	and	scratch	wound	data.	I	interpreted	the	data	I	produced.	I	wrote	
the	results	and	discussion	for	the	data	acquired.	I	made	the	figures	pertaining	to	the	
experiments	I	performed.		
	
	
	
Chapter	2:	MMP-3	Expression	&	Activity	in	C6WT	and	C613	Cell	Lines		
All	 of	 the	 experiments	 in	 Chapter	 2	 were	 carried	 out	 by	 myself	 with	 the	 exception	 of	 the	
experiments	described	in	Figure	2.1.2.	These	experiments	were	performed	by	Q.	Aftab,	M.	Mesnil	
and	V.	Chen	(“Cx43-associated	secretome	and	interactome	reveal	synergistic	mechanisms	for	
glioma	migration	and	MMP3	activation	(In	Review)”),	Q.	Aftab,	M.	Mesnil,	E.	Ojefua,	A.	Poole,	
J.	Noordenbos,	C.	Sitko,	C.	Le,	P.O.	Strale,	N.	Stoynov,	L.J.	Foster,	W.C.	Sin,	C.C.	Naus,	V.C.	Chen,	
currently	in	revision).	The	remainder	of	the	experiments	were	designed	by	me	under	the	guidance	
of	Dr.	Vincent	Chen.	I	carried	out	SDS-PAGE/Western	blots	and	data	analysis	of	MMP-3	in	C6/C6-
13	outlined	(Figure	2.3.2).	The	NFF-3	assay	was	carried	out	by	myself	to	analyze	MMP-3	activity	
in	conditioned	media	of	C6	and	C6-13	cells.		
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Chapter	3:	Synthesis	of	Matrix	Metalloproteinase	3	Inhibitors		
The	synthesis,	and	biological	assay	we	carried	out	by	me	with	the	exception	of	the	in	silico	
molecular	docking.	The	molecular	docking	was	done	in	collaboration	with	members	of	the	
Bushnell	Lab	at	Brandon	University	(Dr.	Eric	Bushnell	and	Chris	Sitko).	The	synthesis	reactions	
were	designed	by	myself	and	Dr.	Bryan	Hill.	The	NFF-3	assay	was	designed	by	myself	under	the	
guidance	of	Dr.	Vincent	Chen.	The	synthesis	reactions	were	carried	out	by	myself,	along	with	
the	NFF-3	assay.	
	
	
Chapter	4:	Chapter	4:	Biological	Effects	of	MMP-3	Inhibition	by	Ilomastat		
All	of	the	experiments	in	Chapter	4	were	performed	by	myself.	The	experiments	were	designed	
by	myself	and	Dr.	Vincent	Chen.	The	aim	of	this	chapter	was	monitor	the	effect	of	ilomastat	
inhibition	on	MMP-3	activity.	I	carried	out	the	flow	cytometry	cytotoxicity,	NFF-3,	and	
zymography	experiments	in	addition	to	the	scratch	wound	assay.	I	carried	out	the	zymography	
assay,	with	protocol	assistance	from	Emmanuel	Ojefua.	
	
	
	
	
	
	
	
	 viii	
Table	of	Contents	
Abstract………………………………………………………………………………………	………….………….………..	iii	
Acknowledgements…………………………………………………………………………………………………......iv	
Preface………………………………………………………………………………………………………………………….vi	 	
Table	of	Contents………………………………………………………………………………………………	……...….viii	 	
List	of	Tables…………………………………………………………………………………………………………..…....xii	
List	of	Figures………………………………………………………………………………………………..……….……..xiii	
List	of	Abbreviations……………………………………………………………………………………………………..xv	
Chapter	1:	General	Introduction…………………………………………………………………………………...1	
1.1 Glioblastoma	Multiforme………………………………………………………………………………...1	
1.1.1 Glioblastoma	Multiforme	Classification………………………………………….5	 	
1.1.2 Glioblastoma	Mutliforme	Subtypes………………………………………………..8	
1.2 Glioblastoma	Multiforme	Migration………………………………………………………………..11	
1.2.1 Molecular	Mechanisms	of	Cell	Migration……………………………………….13	
1.2.2 Glioblastoma	Multiforme	Microenvironment	&	Extracellular	
Matrix………………………........................................................................17	
1.3 Matrix	Metalloproteinases	and	Collagen	ECM	Substrates…….………………………...18	
1.4 Matrix	Metalloproteinases	in	Cancer……………………………………………………………….25	
1.5 A	Summary:	Hypothesis,	Objectives,	and	Aims…………..…………………………………….26	
Chapter	2:	MMP-3	Expression	&	Activity	in	C6	and	C6-13	Cell	Line…………………………………28	
2.1 Introduction…………………………………………………………………………………………………….28	
2.1.1 Methods	to	study	MMPs………………………………………………………………..32	
	 ix	
2.2 Materials	&	Methods……………………………………………………………………………………….34	
2.2.1 C6	Glioma	Culture	and	Protein	Precipitation…………………………………..34	
2.2.2 Bicinchoninic	Acid	Protein	Assay…………………………………………………….34	
2.2.3 Peptide	Sample	Preparation	and	Analysis……………………………………….35	
2.2.4 Western	Blot…………………………………………………………………………………..36	
2.2.5 ImageJ	Analysis………………………………………………………………………………37	
2.2.6 NFF-3	Fluorescence	Assay………………………………………………………………37	
2.3 Results	&	Discussion………………………………………………………………………………………..38	
2.3.1 Secretome	Analysis	of	C6	and	C6-13	Cells………………………………………38	
2.3.2 Western	Blot	of	C6	and	C6-13………………………………………………………..39	
2.3.3 C6	and	C6-13	NFF-3	Fluorescence	Assay…………………………………………41	
2.4 Conclusion……………………………………………………………………………………………………….42	
	
Chapter	3:	Synthesis	of	Matrix	Metalloproteinase	3	Inhibitors………………………………………43	
3.1 Introduction…………………………………………………………………………………………...……….43	
3.2 Materials	&	Methods……………………………………………………………………………………….49	
3.2.1 Chemistry:	General	Procedures………………………………………………………50	
3.2.1.1 Compound	B……………………………………………………………………….50	
3.2.1.2 Compound	C……………………………………………………………………….50	
3.2.1.3 Compound	D	(Leu-Trp)……………………………………………………….51	
3.2.1.4 Compound	E	(AP-1)…………………………………………………………….51	
3.2.1.5 Compound	F	(AP-2)…………………………………………………………….51	
	 x	
3.2.2 In	Silico	Molecular	Docking…………………………………………………………….52	
3.2.3 NFF-3	Fluorescence	Assay………………………………………………………………53	
3.3 Results	&	Discussion………………………………………………………………………………………..53	
3.3.1 Synthesis	of	Ilomastat	Derivatives………………………………………………….53	
3.3.2 Molecular	Docking	of	Ilomastat	Derivatives…………………………………..	57	
3.3.3 NFF-3	of	Ilomastat	and	Synthesized	Compounds……………………………58	
3.4 Conclusion………………………………………………………………………………………………………	61	
Chapter	4:	Biological	Effects	of	MMP-3	Inhibition	by	Ilomastat……………………………………..62	
4.1 Introduction…………………………………………………………………………………………………….62	
4.2 Materials	&	Methods……………………………………………………………………………………….65	
4.2.1 Flow	Cytometry	Cell	Death	Assay…………………………………………………..	66	
4.2.2 NFF-3	Fluorescence	Assay………………………………………………………………67	
4.2.3 Gelatin	Zymography……………………………………………………………………….67	
4.2.4 ImageJ	Analysis………………………………………………………………………………68	
4.2.5 Scratch	Wound	Assay……………………………………………………………………..69	
4.3 Results	&	Discussion………………………………………………………………………………………..69	
4.3.1 Flow	Cytometry	Cell	Death	Assay…………………………………………………..	69	 	
4.3.2 NFF-3	Fluorescence	Assay………………………………………………………………74	
4.3.3 Gelatin	Zymography……………………………………………………………………….76	
4.3.4 Scratch	Wound	Assay……………………………………………………………………..78	
4.4 Conclusion……………………………………………………………………………………………………….85	
Chapter	5:	Overview	of	Research	and	Future	Directions………………………………………………..86	
	 xi	
5.1 Overview	of	Research……………………………………………………………………………………..	86	
5.2 Future	Research	into	MMP-3	and	C6-13	Secretome………………………………………..88	
References…………………………………………………………………………………………………………………….91	
Appendix	1…………………………………………………………………………………………………………………….103	
Appendix	2…………………………………………………………………………………………………………………….104	
Appendix	3…………………………………………………………………………………………………………………….105	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 xii	
List	of	Tables	
Table	1.1.1:	WHO	grading	of	Central	Nervous	System	Tumors………………………………………….5	
Table	1.2.1:	Characteristics	of	Mesenchymal	Migration	Phenotype…………………………………..16	
Table	2.1.1:	Matrix	Metalloproteinase	3	extracellular	matrix	substrates,	non-matrix	substrates,	
and	cellular	sources	of	MMP-3………………………………………………………………………………………….29	
Table	2.2.1:	Liquid	Chromatography,	Mass	Spectrometry,	and	Mascot	Search	Parameters…..35	 	
	
	
	 xiii	
List	of	Figures	
Figure	1.1.1:	Common	mutations	and	effected	signaling	pathways	in	GBM………………………2	
Figure	1.1.2:	Top	30	frequently	mutated	genes	in	GBM…………………………………………………….4	
Figure	1.1.3:	Tissue	sections	of	different	grade	gliomas	following	WHO	classification……….7	
Figure	1.1.4:	Common	genetic	changes	in	primary	GBM	subtypes…………………………………….10	
Figure	1.1.5:	Summary	of	GBM	Classification…………………………………………………………………….11	
Figure	1.2.1:	The	five	steps	of	migration……………………………………………………………………………15	
Figure	1.2.2:	Model	of	ECM	proteins…………………………………………………………………………………17	
Figure	1.3.1:	Five	categories	of	matrix	metalloproteinases………………………………………………..19	
Figure	1.3.2:	MMP	propeptide	cleavage	mechanism…………………………………………………………22	
Figure	1.3.3:	Mechanism	of	MMP	peptide	cleavage………………………………………………………….24	
Figure	2.1.1:	MMP-3	domains……………………………………………………………………………………………28	
Figure	2.1.2:	Scratch	wound	assay	and	secretome	changes	in	C6	versus	C6-13	cells………….31	
Figure	2.1.3:	Mechanism	behind	fluorogenic	substrates……………………………………………………33	
Figure	2.3.1:	Comparison	of	MMP-3	chromatographic	(XIC)	peak	area	of	peptide	
SANAEALMYPVYK	(retention	time	84.0)	from	secretome	of	C6	&	C6-13	…………………………..39	
Figure	2.3.2:	Western	blot	analysis	of	MMP-3	in	C6	and	C6-13	secretome………………………..40	
Figure	2.3.3:	NFF-3	assay	of	MMP-3	activity	in	C6	and	C6-13	secretome…………………………..42	
Figure	3.1.1:	Interaction	of	Batimastat	with	MMP	active	site…………………………………………….45	
Figure	3.2.1:	General	synthesis	scheme	for	derivatives……………………………………………………..49	
Figure	3.3.1:	Proposed	ilomastat	derivatives…………………………………………………………………….54	
Figure	3.3.2:	Interaction	diagrams	for	ilomastat,	Leu-Trp,	AP-1,	and	AP-2…………………………55	
	 xiv	
Figure	3.3.3:	Interaction	diagrams	for	AP-3,	AP-4,	AP-5,	AP-6,	and	AP-7……………………………56	
Figure	3.3.4:	Inhibition	of	MMP-3	activity	detected	by	NFF-3	assay…………………………………..60	
Figure	4.1.1	Flow	cytometry	mechanism…………………………………………………………………………..63	
Figure	4.3.1:	Cytotoxicity	of	ilomastat	after	24	hours………………………………………………………..71	
Figure	4.3.2:	Cytotoxicity	of	ilomastat	after	72	hours………………………………………………………..73	
Figure	4.3.3:	Inhibition	of	MMP-3	activity	by	varying	ilomastat	concentrations………………...75	
Figure	4.3.4:	Gelatin	zymography	of	varying	ilomastat	treatments……………………………………77	
Figure	4.3.5:	Low	glucose	media	migration	for	control,	25	µM,	and	50	µM	at	0,	24,	and	48	
hours…………………………………………………………………………………………………………………………………79	
Figure	4.3.6:	Low	glucose	media	migration	for	75	µM,	and	100	µM	at	0,	24,	and	48	hours…80	
Figure	4.3.7:	High	glucose	media	migration	for	control,	25	µM,	and	50	µM	at	0,	24,	and	48	
hours…………………………………………………………………………………………………………………………………81		
Figure	4.3.8:	High	glucose	media	migration	for	75	µM,	and	100	µM	at	0,	24,	and	48	hours…82	
Figure	4.3.9:	Relative	migration	of	each	ilomastat	treatment	for	low	glucose	and	high	glucose				
media	at	24	and	48	hours………………………………………………………………………………………………….83	
Figure	5.2.1:	MMP-3	active	site	with	amino	acid	preference	for	each	subsite…………………..90	
	 	
	 xv	
List	of	Abbreviations	
	
BCA	 	 	 Bicinchoninic	Acid	
BSA	 	 	 Bovine	Serum	Albumin	
CM	 	 	 Conditioned	Media	
COSMIC	 	 Catalogue	of	Somatic	Mutations	in	Cancer	
DCM	 	 	 Dichloromethane	
DIC	 	 	 N,N'-Diisopropylcarbodiimide 
DMF	 	 	 Dimethylformamide	
DMSO	 	 	 Dimethyl	Sulfoxide	
Dnp	 	 	 N-2,4-dinitrophenyl	
DTT	 	 	 Dithiothreitol	
ECL	 	 	 Enhanced	Chemiluminescence	
ECM	 	 	 Extracellular	Matrix	
EtOH	 	 	 Ethanol	
FBS	 	 	 Fetal	Bovine	Serum	
Fmoc	 	 	 Fluorenylmethyloxycarbonyl 
GBM	 	 	 Glioblastoma	Multiforme	
IDH	 	 	 Isocitrate	dehydrogenase	
LC-MS/MS	 	 Liquid	Chromatography	Mass	Spectroscopy/Mass	Spectroscopy	
M	 	 	 Molarity	
Mca	 	 	 (7-methoxycoumarin-4-yl)acetyl	
MeOH	 	 	 Methanol	
mL	 	 	 Milliliter	
MMP	 	 	 Matrix	Metalloproteinase	
MMPI	 	 	 Matrix	Metalloproteinase	Inhibitor	
MOE	 	 	 Molecular	Operating	Environment	
MS	 	 	 Mass	Spectroscopy	
NMR	 	 	 Nuclear	Magnetic	Resonance	
	 xvi	
PBS	 	 	 Phosphate	Buffered	Saline	
PDB	 	 	 Protein	Data	Bank	
PI	 	 	 Propidium	Iodide	
TBST	 	 	 Tris-buffered	Saline	with	Tween	20	(Polysorbate	20)	
TCGA	 	 	 The	Cancer	Genome	Atlas	
THF	 	 	 Tetrahydrofuran	
TLC	 	 	 Thin	Layer	Chromatography		
TNBS	 	 	 2,	4,	6	–	trinitrobenzenesulfonic	acid	
Tp53	 	 	 Tumor	protein	53	
SDS	 	 	 Sodium	Dodecyl	Sulfate	
SILAC	 	 	 Stable	Isotope	Labeling	with	Amino	Acids	in	Cell	Culture	
UV	 	 	 Ultraviolet		
WHO	 	 	 World	Health	Organization	
WR	 	 	 Working	Reagent	
ZBG	 	 	 Zinc	Binding	Group	
	 1	
Chapter	1:	General	Introduction	
	
Cancer	 is	 a	 disease	 that	 has	 an	 impact	 on	 the	 lives	 of	 many	 humans.	 The	 World	 Health	
Organization	(WHO)	estimates	the	number	of	cancer	cases	rising	from	1.3	to	2.1	million	from	
2012	 to	 2030,	 in	 North	 and	 South	 America	 alone.1	 In	 addition,	 the	 number	 of	 Canadians	
diagnosed	with	cancer	within	their	lifetime	is	approximately	1	in	2.2	Cancer	is	the	uncontrolled	
division	of	cells	resulting	in	tumor	formation.	The	cause	of	this	uncontrolled	division	is	due	to	
genetic	 mutations,	 may	 that	 be	 due	 to	 environmental	 conditions,	 lifestyle,	 or	 genetic	
predisposition	to	given	mutations.	Given	that	cancer	is	a	disease	that	will	have	an	impact	on	our	
lives	directly	or	indirectly,	it	is	important	for	continuing	research	on	the	mechanisms	of	cancer,	
including	causation,	progression,	invasion,	and	treatment.	This	thesis	will	focus	on	the	protease	
matrix	metalloproteinase	3	and	the	inhibition	of	the	protease	through	development	of	peptide-
based	inhibitors.	The	development	of	these	compounds	may	offer	insight	into	the	mechanism	of	
cancer	invasion	while	providing	new	avenues	to	inhibit	the	malignant	tumours	of	the	brain.		
1.1 Glioblastoma	Multiforme	
Glioblastoma	Multiforme	(GBM)	is	an	aggressive	and	most	common	form	of	primary	brain	tumor.	
Occurring	mostly	within	the	cerebral	hemisphere,	GBM	may	also	occur	in	other	regions	of	the	
brain,	as	well	as	the	brain	stem	and	spinal	cord. GBM,	a	high	grade	glioma,	can	arise	from	neural	
stem	cells,	differentiated	glial	cells	that	have	acquired	stem-cell	like	properties,	and	through	de-
differentiation	of	astrocytes,	oligodendrocytes	and	ependymal	cells.3	Classified	as	the	highest	
grade	(grade	IV),	GBM	has	an	incidence	of	3-4/100,000	with	the	incidence	increasing	with	age.4	
Survival	after	GBM	diagnosis	 is	 still	 short,	with	majority	of	patients	 surviving	between	15	 -18	
	 2	
months	after	diagnosis,	and	only	approximately	10%	surviving	past	five	years.4	The	short	term	
survival	of	patients	is	due	to	ill-defined	tumors,	tumor	reoccurrence,	and	resistance	to	therapy.	
The	causation	of	GBM	is	most	likely	due	to	genetic	mutation	and	its	aggressiveness	due	to	the	
expression	of	these	mutations.	
	
Figure	 1.1.1:	 Common	 mutations	 and	 effected	 signaling	 pathways	 in	 GBM.	 Adapted	 from	
McLendon	et	al.	2008.5	
	 	
In	order	for	any	type	of	cancer	to	develop,	key	genetic	events	must	occur.	In	GBM,	the	
most	common	genetic	events	include:	(1)	inactivation	of	the	p53	mutation	and	retinoblastoma	
tumor	 suppressor	 pathway	 leading	 to	 uncontrolled	 proliferation;	 (2)	 activation	 of	
phosphatidylinositol-3-OH	kinase	(PI3K)	pathway	(PTEN	is	a	PI3K	pathway	antagonist	and	most	
common	mutation	 Figure	 1.1.2);	 and	 (3)	mutational	 activation	 and	 amplification	 of	 receptor	
tyrosine	kinase	(RTK)	leading	to	the	dysregulation	of	growth	factor	signaling,	such	as	epidermal	
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growth	factor	receptor	(EGFR)	(Figure	1.1.1).5,6	The	commonly	mutated	genes,	TP53,	RB1	(tumor	
suppressor),	PIK3R1	(PI3K	pathway),	PTEN,	and	EGFR	are	all	within	the	top	30	of	the	frequently	
mutated	genes	(Figure	1.1.2)	from	The	Cancer	Genome	Atlas	(TCGA)	project	TCGA-GBM.7	The	
number	and	type	of	genetic	mutations	produce	varying	tumors,	which	can	be	classified	to	give	
general	tumor	malignancy.	
	
Figure	1.1.2:	Top	30	frequently	mutated	genes	in	GBM.	The	top	30	out	of	17449	most	frequently	
mutated	genes	in	GBM.	Data	was	from	TCGA	and	plotted	as	a	percentage	of	mutations	detected	
from	the	total	number	of	samples	acquired.7	
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1.1.1	Glioblastoma	Multiforme	Classification		
	
The	WHO	 uses	 a	 grading	 system	 to	 classify	 gliomas	 through	 characteristics	 to	 predict	 tumor	
malignancy.	Gliomas	are	classified	based	upon	the	cellular	morphology	of	the	tumor	cells,	which	
may	 include	 tumors	 such	 as	 astrocytoma,	 epedymoma,	 oligoastrocytoma,	 and	
oligodendroglioma.	 In	addition	to	classifying	gliomas	based	upon	cell	type,	tumors	are	graded	
based	on	the	biological	behavior	and	morphology	of	the	tumor,	giving	a	malignancy	scale	of	the	
tumor.	The	WHO	uses	a	scale	from	grade	I	to	grade	IV,	with	malignancy	increasing	as	the	grade	
increases	(Table	1.1.1).	A	summary	of	the	grading	scale	and	an	example	of	an	astrocytic	tumor	of	
that	grade	is	outlined	in	Table	1.1.1.	
	
Table	1.1.1:	WHO	grading	of	Central	Nervous	System	Tumors8,9	
Grade	 Characteristic	 Astrocytic	Tumor	
	
	
I	
Non-malignant/least	malignant	
Low	proliferative	potential	
Normal	cell	morphology	
Minimal	reoccurrence	
Generally	long-term	survival	
	
	
Pilocytic	Astrocytoma	
	
	
II	
Generally	infiltrates	nearby	tissue	
Low-level	proliferation	
Slightly	abnormal	morphology	
May	recur	as	higher	grade	
Survival	of	more	than	5	years	
	
	
Diffuse	Astrocytoma	
	
	
III	
Infiltrates	and	affects	nearby	tissue	
	Proliferative	
Abnormal	morphology	
Reoccurrence,	often	as	higher	grade	
Survival	of	2-3	years	
	
	
Anaplastic	Astrocytoma	
	
	
IV	
Invasive,	blood	vessel	formation	
Highly	proliferative	
Very	abnormal	morphology	
Reoccurrence,	necrosis	
Fatal	outcome	(approximately	1	year)	
	
	
Glioblastoma		
	
	 5	
The	WHO	classification	of	gliomas	is	the	most	widely	used	classification	system	and	overall	
provides	a	means	of	placing	tumors	into	specific	categories.	However,	classification	schemes	
that	are	based	upon	visual	characteristics	(Figure	1.1.3),	dependent	on	the	observer,	and	can	be	
difficult	to	place	into	one	grade.10	Furthermore,	the	WHO	classification	does	not	predict	the	
aggressiveness,	therapeutic	response,	and	survival	of	individual	patients.10	The	alternative	
route	for	classification	is	separating	tumors	based	upon	genetic	mutations.			
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Figure	 1.1.3:	 Tissue	 sections	 of	 different	 grade	 gliomas	 following	 the	 WHO	 classification	
system.	Classification	of	glioma	grade	based	upon	visual	characteristics.	A)	Glioblastoma	(Grade	
IV),	 B)	 Anaplastic	 Astrocytoma	 (Grade	 III),	 C)	 Diffuse	 Astrocytoma	 (Grade	 II).	 Variation	 of	
classification	can	be	different	from	observer	to	observer	as	visual	observation	varies	between	
individuals.	Adapted	from	Buczkowicz	et	al.	2015.11		
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	 GBM	 can	 be	 divided	 into	 two	 types,	 primary	 or	 secondary,	 with	 the	 primary	 GBM	
occurring	de	novo,	and	the	secondary	GBM	progressing	from	a	lower	grade	glioma	(grade	II	or	
III)	to	grade	IV	GBM.	Patients	in	the	primary	glioblastoma	group	account	for	90%	of	glioblastoma	
cases,	and	occurs	primarily	in	patients	over	the	age	of	55.12	Secondary	glioblastoma	accounts	for	
about	 10%	 of	 GBM	 cases,	 and	 is	 generally	 associated	 with	 younger	 patients12	 Another	
distinguishing	characteristic	between	primary	and	secondary	GBM	 is	 the	mutational	 status	of	
isocitrate	dehydrogenase	(IDH),		with	primary	GBM	maintaining	the	wild	type	version	of	the	IDH	
gene	and	secondary	GBM	having	the	IDH-mutant	gene.13		IDH	is	an	enzyme	of	the	citric	acid	cycle	
that	might	play	a	 role	 in	 cellular	defense	against	oxidative	 stress,	which	may	account	 for	 the	
better	 outcome	 of	 patients	 that	 carry	 this	 mutation.14	 Patients	 diagnosed	 with	 primary	
glioblastoma	(IDH	wild	type)	have	a	median	survival	of	11	–	13	months,	whereas	patients	with	
secondary	glioblastoma	(IDH	mutation)	survival	is	27	–	31	months.15			While	the	tumors	may	be	
divided	into	primary	or	secondary	GBM	based	upon	GBM	progression	(de	novo	or	progressive)	
and	 IDH	mutation	 status,	morphologically	 and	 clinically	 these	 two	 are	 indistinguishable.	 The	
inability	to	distinguish	morphology	results	in	difficulties	with	diagnosis	and	treatment.	However,	
due	to	the	advances	in	genomic	sequencing,	GBM	can	be	divided	into	molecular	subclasses.	
	
	
	
1.1.2	Glioblastoma	Multiforme	Subtypes	
Until	 recently	 gliomas	 were	 classified	 based	 upon	 histological	 criteria.	 In	 2006,	 molecular	
subclasses	or	subtypes	were	developed	to	better	predict	outcome	and	the	clinical	response	to	
treatment.	These	subtypes	were	developed	based	upon	the	key	molecular	events	that	occur	in	
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tumor	development,	such	as	changes	in	signaling	pathways	and	gene	expression.16	The	subtypes	
were	defined	by	clustering	of	the	expression	of	survival-related	genes,	resulting	in	three	discrete	
subtypes.16	A	set	of	35	signature	genes	were	derived	to	be	used	by	clustering	techniques	to	assign	
high	 grade	 glioma	 tumors	 to	 an	 appropriate	 subtype,	 these	 subtypes	 being:	 proneural,	
proliferative,	and	mesenchymal.16	Adding	on	to	the	work	done	by	Philips	et	al.	(2006),	a	further	
subtype	was	identified	by	using	200	GBM	and	two	normal	brain	samples	to	identify	210	signature	
genes	 per	 subtype.17	 The	 four	 subtypes	 redefined	 as	 proneural,	 neural,	 classical,	 and	
mesenchymal.		
	 The	proneural	subtype	is	generally	found	in	younger	patients	with	secondary	GBM,	and	
have	 characteristics	 similar	 to	 oligodendroglial	 cells.18	 Proneural	 is	 characterized	 by	 its	 IDH1	
mutation,	in	addition	to	the	proneural	expression	markers	such	as	SOX,	DCX,	DLL3,	ASCL1,	TCF4	
and	the	oligodendrocytic	expression	markers	PDGFRA,	OLIG2,	TCF3,	NKX2-2	(Figure	1.1.4).19	The	
neural	subtype	arises	from	astrocyte	and	oligodendrocyte	cells	and	expresses	high	levels	of	EGFR,	
but	maintains	gene	signatures	of	normal	brain	cells	and	has	the	neuron	expression	markers	NEFL,	
GABRA1,	 SYT1,	 SLC12A5	 (Figure	 1.1.4).18,19	 The	 neural	 subtype	 is	 the	 least	 defined	 of	 all	 the	
subtypes.	Classical	GBMs	have	characteristics	of	astrocytes,	while	expressing	markers	of	stem	
cells	and	neuron	precursors.18	Similar	to	the	neural	subtype,	classical	GBM	also	have	an	EGFR	
mutation,	overexpression,	or	amplification.	The	Notch	and	Shh	pathways	are	also	activated	in	
the	 classical	 subtype	 (Figure	1.1.4).19	 The	mesenchymal	 subtype	has	 similar	 characteristics	 as	
astrocytic	gliomas,	occurs	in	patients	over	the	age	of	50	and	has	poor	prognosis	which	could	be	
due	to	the	mutation	or	loss	of	function	in	genes	such	as	TP53,	NF1,	and	PTEN	(Figure	1.1.4).16,19		
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Figure	1.1.4:	Common	genetic	changes	in	primary	GBM	Subtypes.	Primary	subtypes	including;	
classical,	mesenchymal,	neural,	and	proneural	subtypes.	Common	genetic	changes	in	secondary	
GBM	are	also	included.	Adapted	from	Van	Meir	et	al.	2010.19	
	 	
In	summary,	gliomas	are	graded	by	the	WHO	classification,	with	GBM	being	a	grade	IV.	
GBM	is	then	classified	as	primary	or	secondary	GBM	based	on	the	progression	of	the	tumor	and	
the	IDH	mutation.	Finally,	GBM	can	be	divided	into	the	subtypes	classical,	mesenchymal,	neural,	
and	proneural	based	on	genetic	mutations	 (Full	 summary	of	GBM	classification	Figure	1.1.5).		
While	being	able	to	genetically	categorize	tumors	may	lead	to	more	targeted	therapeutics,	even	
after	 95%	 of	 tumor	 is	 removed,	 the	 invasiveness	 of	 GBM	 leads	 to	 formation	 of	 tumors	 at	
secondary	 sites.	 To	 help	 prevent	 secondary	 tumors	 from	 forming,	 more	 knowledge	 and	
treatment	strategies	to	address	malignant	glioma,	including	GBM,	are	urgently	needed.	
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Figure	1.1.5:	Summary	of	GBM	Classification.	GBM	is	a	IV	WHO	glioma	divided	into	primary	or	
secondary.	GBM	is	further	classified	as	the	subtype	classical,	mesenchymal,	neural,	or	proneural.	
1.2 Glioblastoma	Multiforme	Migration	
Migration	 is	 a	multistep	 process	 due	 to	 a	 combination	 of	 cellular	 and	molecular	 events.20,21		
Typically	a	phenotype	with	stem	cell	likeness	and	the	ability	to	degrade	extracellular	matrix	(ECM)	
components	results	in	a	greater	ability	for	invasiveness.22	For	migration	to	occur	there	must	be	
the	detachment	of	tumor	cells,	the	adherence	of	tumor	cells	to	the	ECM,	and	the	migration	of	
tumor	cells	into	the	surrounding	tissue.23		
	 Invasive	tumor	cells	will	polarize,	and	will	change	shape	to	a	spindle-like	morphology,	with	
protrusions	that	can	attach	to	components	of	the	ECM	and	pull	the	cell	along.24,22	Proteases	are	
involved	to	degrade	and	modify	the	ECM,	creating	space	for	the	cell	to	move.25	Included	in	these	
proteases	are	matrix	metalloproteinases	(MMPs)	and	endopeptidases	that	are	 involved	in	the	
physiological	and	pathological	remodeling	of	the	ECM.26,27	The	remodeling	of	the	ECM	enhances	
the	invasion	potential	of	GBM.25		
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	 Another	factor	that	influences	remodeling	of	the	ECM,	and	thus	invasion,	is	the	hypoxic	
condition	of	 the	microenvironment.28	Hypoxia	 is	 a	 state	 in	which	oxygen	 levels	 are	 low.	 Low	
oxygen	conditions,	or	hypoxic	conditions	are	common	in	areas	that	surround	necrotic	areas	of	
tumors.29	Often	tumor	hypoxia	is	associated	with	tumor	progression	and	the	aggressiveness	of	
the	 tumor.	 Hypoxia-inducible	 factors	 (HIF-1),	 regulate	 the	 cell	 response	 to	 hypoxia	 by	
transcriptional	 activation	 of	 downstream	 genes.30,31	 Activation	 of	 these	 downstream	 genes	
include	genes	involved	with	migration	and	invasion.31	HIF-1,	a	transcription	factor,	is	composed	
of	 HIF-1a	 (or	 analogs	 HIF-2a,	 HIF-3a)	 and	 HIF-1b.32,33	 HIF-1a,	 the	 most	 important	 subunit,	
dimerizes	with	HIF-1b,	which	is	the	constitutively	active	subunit,	to	prevent	degradation	of	HIF-
1,	 thus	 recruiting	 transcriptional	 co-activators	and	 initiating	gene	 transcription.20,34	GBM	cells	
overexpress	HIF-1a,	and	glioma	stem-like	cells	also	overexpress	HIF-2a.35		In	normoxic	conditions	
HIF-1a	has	a	half-life	of	approximately	5	minutes,	but	under	hypoxic	conditions	is	much	more	
stable	 due	 to	 several	 pathways.36	 The	 increased	 activation	 of	 HIF-1,	 leads	 to	 increased	
transcription	of	genes	associated	with	migration	and	invasion	including	ECM	remodeling	enzymes	
(MMPs,	cathepsins)	and	matricellular	proteins.	
In	 addition,	 to	 the	 increased	 activation	 of	 HIF-1	 hypoxic	 conditions	 can	 promote	 the	
reprogramming	of	non-stem-like	cells	into	stem-like	cells.30	These	changes	are	believed	to	play	a	
critical	role	in	the	migration	and	invasion	of	GBM,	including	the	formation	of	pseudopalisades	or	
necrotic	areas	comprised	of	hypercellular	zones	unique	to	GBM.30	
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1.2.1	Molecular	Mechanisms	of	Cell	Migration	
Migration	 is	 directly	 connected	 to	 the	 microenvironment	 surrounding	 the	 cell.	 In	 order	 to	
migrate,	 the	 cell	 must	 modify	 its	 shape,	 which	 includes	 the	 cell	 becoming	 polarized	 and	
elongated.		
Overall,	there	are	five	steps	to	migration:	1)	The	first	step	is	the	protrusion	of	the	leading	
edge	 of	 the	 cell.	 (Figure	 1.2.1	 1)	 This	 protrusion	 is	 created	 by	 actin	 filaments	within	 the	 cell	
connecting	to	adaptor	proteins,	resulting	in	the	cell	membrane	being	pushed	outward,	elongating	
the	cell.37	In	addition	to	the	leading	edge	of	the	migrating	cell,	necrotic	areas	of	the	tumor	express	
cells	 with	 pseudopalisades.30	 These	 populations	 of	 pseudopalisades	 characteristically	 express	
more	stem	cell-like	markers	and	migrate	away	from	the	hypoxic	regions.30,38	The	pseudopalisades	
are	believed	to	be	connected	to	the	aggressiveness	and	malignancy	of	GBM.38	Pseudopalisades	
overexpress	HIF-1a	 than	compared	to	adjacent	 tumor	cells.38,39	The	HIF-1a	 is	 localized	to	the	
leading	invasive	edge	of	the	tumor	and	the	genes	regulated	by	HIF-1a	control	the	amount	of	ECM	
degradation,	 and	 therefore	 the	 invasiveness.29	 2)	 The	 second	 step	 is	 ECM	 interaction	 and	
formation	of	focal	contacts	(Figure	1.2.1	2).	The	leading	edge	of	the	cell	then	comes	in	contact	
with	 the	 adjacent	 ECM	 and	 binds	 to	 the	 ECM	 via	 integrins,	 creating	 focal	 contacts.40	 3)	 The	
recruitment	of	proteases.	The	involvement	of	integrins	signals	for	surface	proteases	to	become	
concentrated	 near	 cell-matrix	 interactions.37,41	 Close	 to	 the	 cell	 surface,	 proteases	 (including	
MMPs)	cleave	ECM	components	such	as	collagen,	fibronectin,	 laminin,	etc.,	and	pro-MMPs	to	
generate	active	MMPs.37	The	protease	ECM	degradation	creates	space	required	for	migration,	as	
the	cell	continues	moving	away	from	the	tumor,	creating	tube-like	tracts	through	the	ECM	along	
its	migration	track.37,42	4)	In	the	fourth	step	of	migration	active	myosin	II	binds	to	actin	filaments	
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to	generate	the	contraction	of	actomyosin.37	The	activation	of	myosin	II	by	the	phosphorylation	
of	 the	 myosin	 light	 chain	 by	 the	 calmodulin-dependent	 myosin	 light-chain	 kinase,	 aids	 in	
contraction.37	5)	The	final	step	of	the	migration	process	is	the	detachment	of	the	trailing	end	of	
the	cell.	Focal	contacts	components	at	the	trailing	edge	are	cleaved	by	the	cytoplasmic	protease	
calpain.37	Focal	contacts	are	weakened	by	cleavage	of	adhesion	receptors	by	proteolytic	enzymes	
sheddases.37	 The	 accumulation	 of	 cleaved	 collagen	 fragments	 generated	 by	 the	 forward	
movement	of	the	cell	aids	in	further	weakening	focal	contacts.37	After	focal	contacts	have	been	
detached,	integrins	detach	from	the	substrate,	become	internalized,	and	are	either	recycled	or	
deposited	on	the	substrate.37	
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Figure	1.2.1:	The	five	steps	of	migration.	The	top	left	image	shows	where	each	step	of	migration	
is	 occurring	 in	 relation	 to	 the	 cell.	 1	 The	 protrusion	 of	 the	 leading	 edge	 of	 the	 cell.	 2	 ECM	
interaction	and	formation	of	local	contacts.	3	Recruitment	of	proteases	(MMPs).	4	Contraction	
of	actomyosin.	5	Detachment	of	trailing	end.	Modified	from	Friedl	et	al.	2003.37	 	
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There	are	two	types	of	migration	that	cells	follow,	amoeboid	migration	and	mesenchymal	
migration.	 In	amoeboid	migration,	 there	 is	no	proteolytic	ECM	remodeling,	 cells	 rely	on	path	
finding	 and	 squeezing/flowing	 through	 spaces	 in	 the	 ECM.	 Cells	 that	 fit	 into	 mesenchymal	
migration	follow	the	migration	mechanism	outlined	above	(Figure	1.2.1).	The	types	of	cells	that	
follow	mesenchymal	migration	are	primarily	from	connective-tissue	tumors,	such	as	GBM.	These	
type	 of	 cells	 have	 a	 spindle-shape	morphology	 similar	 to	 fibroblasts	 due	 to	 the	 adhesion	 of	
integrins.37	The	maintenance	of	this	phenotype	and	migration	require	the	activation	of	MMPs.37	
An	outline	of	the	characteristics	of	a	mesenchymal	phenotype	is	located	in	Table	1.3.1.	
	
Table	1.2.1:	Characteristics	of	Mesenchymal	Migration	Phenotype	(adapted	from	Friedl	et	al.	
Nature	Reviews	Cancer,	2003)37	
Characteristic	 Mesenchymal	Phenotype	
Cancer	Types	 Glioblastoma,	Fibrosarcoma	
Cell	Shape	 Fibroblast-like,	elongated	(length	50-200µm)	
Growth	in	Culture	 Adhesive	
Migration	Velocity	 Low	(0.1-1	µm/min)	
Cellular	Migration	Mechanism	 Traction	dependent	
Adhesion-force	generated	 High,	fiber	bundling	and	pulling	
Cell-matrix	interactions	 Integrins	and	proteases	focalize	
Proteolytic	ECM	Remodeling	 Present	to	extensive	
Mechanism	for	overcoming	matrix	barriers	 Generating	tube	like	deficits	through	ECM	by	
proteolysis		
	
1.2.2	Glioblastoma	Multiforme	Microenvironment	&	Extracellular	Matrix	
The	interactions	between	of	GBM	and	the	microenvironment	regulate	invasion	into	healthy	brain	
tissue	 to	 occur.	 Thus,	 the	 composition	 of	 exogenous	 factors	 contained	 within	 the	 tumour	
microenvironment	plays	an	important	role.	In	particular	the	ECM	of	brain	tumors	such	as	GBM	
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often	consist	of	basement	membrane	proteins	that	line	the	blood	vessels,	including	collagen	IV,	
laminin,	 fibronectin,	 and	 proteins	 surrounding	 the	 tumor,	 including	 collagen	 I,	 tenascin-C,	
vitronectin,	and	hyaluronan	(Figure	1.3.1).43	
	
Figure	1.2.2:	Model	of	ECM	proteins.	Proteins	include	collagen,	fibronectin,	integrins,	and	
proteoglycan	complexes.		
	
Amongst	these,	GBM	migration	is	stimulated	by	collagen	IV,	fibronectin,	tenasin-C,	and	
vitronectin.44,45	Here,	the	mechanical	tension	provided	by	a	dense	ECM	environment	causes	
GBM	cells	to	switch	to	a	migratory	phenotype..46	The	ECM	also	acts	as	scaffold	for	adhesion	
proteins	such	as	integrins,	to	promoting	migration	via	actin	dynamics.		
	 Integrins	are	transmembrane	glycoproteins	that	consist	of	two	subunits	(a	and	b),	and	
are	key	to	cell-ECM	interactions,	providing	the	adhesion	for	migratory	cells	to	pull	themselves	
along	ECM	components.	Integrins	can	interact	with	ECM	proteins	such	as	fibrinogen,	
fibronectin,	and	vitronectin.	The	intergins	themselves	have	no	proteolytic	activity,	however	the	
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adhesion	of	integrins	to	ECM	proteins	can	trigger	signal	transduction	pathways	that	lead	to	the	
creation	of	binding	sites	for	enzymes	such	as	matrix	metalloproteinases.44		
	
1.3 Matrix	Metalloproteinases	and	Collagen	ECM	Substrates	
Matrix	metalloproteinases	(MMPs)	are	a	family	of	structurally	related	zinc	endopeptidases	
involved	in	both	physiological	and	pathological	remodeling	of	the	ECM.26,47	The	activity	of	
MMPs	was	first	discovered	in	1962,	where	the	ECM	proteins	were	shown	to	be	degraded	by	
collagenolytic	activity	in	the	tails	of	tadpoles.48	Since	then,	more	than	26	MMPs	have	been	
identified	and	placed	into	one	of	five	categories	due	to	their	substrate	specificity	or	their	
structure/function.49	These	five	categories	being:	collagenases,	gelatinases,	stromelysins,	
membrane-type	MMPs,	and	others	(Figure	1.3.1).49	
	
Figure	1.3.1:	Five	categories	of	matrix	metalloproteinases.	Categories	include	the	gelatinases,	
collagenases,	stromelysins,	membrane-type,	and	others.	
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Invasion	cannot	occur	without	ECM	remodeling,	since	the	ECM	can	be	both	a	substrate	and	
barrier	to	invasion.	The	MMPs	are	the	primary	proteases	responsible	for	the	turnover	and	
remodeling	of	the	ECM.27	MMPs	have	the	ability	to	degrade	various	components	of	the	ECM	
and	of	basement-membranes	such	as:	aggrecan,	elastin,	fibronectin,	gelatin,	laminin	and	
collagen.50	In	a	normal	adult	brain,	collagen	levels	are	relatively	low,	however	in	GBM,	collagen	
levels	are	elevated		due	to	the	fact	that	GBM	cells	remodel	the	ECM	by	degrading	existing	
components	and	secreting	new	ECM	proteins,	including	collagen.43	MMPs	are	key	proteases	to	
the	ECM	remodeling	and	are	important	to	collagen	turnover.	Out	of	the	family	of	MMPs,	14	are	
known	to	degrade	various	types	of	collagens.	MMPs	play	a	role	in	regulating	the	interaction	
between	collagen	and	its	receptors,	while	also	being	regulated	by	pathways	activated	by	
collagen.43		
As	a	principle	substrate	of	MMPs,	there	are	29	collagen	types	that	can	be	group	into	three	
different	classes.	Collagen	type	I	is	one	of	the	main	type	of	collagens	in	connective	tissue,	with	
three	alpha	collagen	chains	wound	together	to	form	a	superhelix	structure	that	provides	the	stiff	
framework	of	collagen	fibrils.51	A	collagen	chain	is	composed	of	four	domains:	the	signal	peptide	
domain,	 the	 N-terminal	 propeptide	 domain,	 collagen	 chain	 domain,	 and	 the	 C-terminal	
propeptide	domain.	Collagen	type	I	is	secreted	as	procollagen	and	thus	the	propeptide	domains	
must	be	cleaved	before	the	collagen	can	form	fibrils.	During	invasion,	collagen	is	believed	to	have	
three	primary	roles	in	GBM.	The	first	role	is	to	provide	adhesion	for	cells,	which	is	important	in	
terms	 of	 migration.43	 Collagen	 can	 also	 act	 as	 a	 storage	 systems	 for	 growth	 factors,	
proteoglycans,	 etc.	 which	 can	 be	 released,	 through	 collagen	 remodeling,	 based	 upon	 the	
microenvironment.43	 The	 third	 role	 of	 collagen	 is	 acting	 as	 a	 ligand	 for	 receptors	 in	 signal	
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transduction	pathways	that	are	required	for	processes	such	as	invasion.43		
Similar	to	collagen,	fibronectin	is	expressed	in	higher	levels	in	GBM	than	in	normal	brain	
tissue.52	Fibronectin	facilitates	collective	invasion	through	fibronectin	degradation.52	In	human	
A375	melanoma	cells,	it	has	been	shown	that	MMP-2	is	recruited	to	the	leading	edge	of	leading	
edge	of	invasive	cells	where	it	cleaves	fibronectin	into	shorter	fragments.53	These	fragments	of	
fibronectin	facilitate	adhesion	and	migration	of	tumor	cells	through	the	integrin	avb3.53	
Due	to	their	ability	to	degrade	the	ECM	and	basement-membranes,	MMPs	are	tightly	
regulated	at	both	the	transcription	and	protein	levels.54	Under	normal	conditions		mRNA	
expression	is	low,	however	when	ECM	remodeling	is	required	such	as	with	wound	healing,	
mRNA	levels	are	upregulated.54	In	addition	to	the	regulation	at	the	transcription	level,	MMPs	
are	synthesized	as	inactive	zymogens,	and	can	only	be	activated	through	the	proteolytic	
cleavage	of	the	prodomain	(propeptide	domain).54	Active	MMPs	are	further	regulated	by	their	
endogenous	inhibitors,	tissue	inhibitors	of	metalloproteinases	(TIMPs).	There	are	four	TIMPs	in	
total,	and	inhibit	MMPs	by	binding	tightly	to	the	active	site	via	non-covalent	bonds,	inactivating	
the	enzyme.55	Decreased	levels	of	TIMPs	and	an	increased	expression	of	MMPs	has	been	
associated	with	tumorgenesis.47,55		 		
In	order	to	have	the	greatest	ability	to	inhibit	MMPs,	understanding	the	structure	of	these	
proteins	and	catalytic	mechanism	of	the	active	site	is	key.		MMPs	are	multi-domain	proteins	
approximately	130-260	residues	in	length,	that	have	a	highly	conserved	propeptide	and	
catalytic	domains	amongst	the	MMPs.48,54	MMPs	are	synthesized	as	inactive	zymogens.	This	
initial	inactivity	is	due	to	the	propeptide	domain	that	blocks	the	active	site.	The	propeptide	
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domain	contains	approximately	80	residues	and	has	a	conserved	‘cysteine	switch’	at	the	N-
terminal	end	that	disrupts	the	interaction	between	the	catalytic	zinc	ion	in	the	active	site	and	a	
cysteine	residue	in	the	propeptide	domain	(Figure	1.3.2).48,54		The	sulfhydryl	group	of	the	
cysteine	residue	coordinates	to	the	zinc	ion,	keeping	it	inactive.54	The	removal	of	the	
propeptide	domain	by	serine	proteinases	or	other	MMPs	destabilizes	the	zinc-cysteine	
interaction,	activating	the	MMP.48	The	substrate	variation	amongst	MMP	members	is	due	to	
the	specificity	of	subsites	or	subpockets.		
	 21	
	
Figure	1.3.2:	Propeptide	cleavage	and	mechanism	of	MMP	activation.	MMPs	are	secreted	in	
the	inactive	pro-MMP	form	with	the	cysteine	residue	coordinated	to	the	catalytic	zinc.	The	
propeptide	domain	is	removed	by	serine	proteases	or	other	MMPs,	resulting	in	a	catalytically	
active	MMP,	with	a	water	bound	to	the	zinc	ion	that	can	coordinate	to	the	glutamate	R-group.	
Modified	from	Rossello	et	al.	2009.56		
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The	conserved	catalytic	domain	among	MMPs	contain	a	catalytic	Zn2+	ion,	a	structural	Zn2+	
ion,	and	one	to	three	Ca2+	ions	that	contribute	to	the	stability	of	the	MMP.54	The	catalytic	zinc	
ion	is	coordinated	by	three	histidine	residues	in	a	HEXGHXXGXXH	motif.48,54	All	MMPs	also	
contain	a	conserved	methionine	residue	with	a	Met-turn.48	The	active	site	also	contains	an	
axially	coordinated	water	molecule	that	is	hydrogen	bonded	to	the	carboxylate	group	of	a	
glutamic	acid	residue	that	is	responsible	for	cleaving	peptide	bonds	(Figure	1.3.3).54			
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Figure	1.3.3:	Mechanism	of	MMP	peptide	cleavage.		(a)	Catalytic	zinc	ion	is	tetrahedrally	
coordinated	to	three	histidines	and	a	water	molecule.	(b)	Water	donates	proton	to	glutamine	
(Glu)	peptide	binds	to	catalytic	site.	(c)	Proton	transferred	to	nitrogen	of	scissile	amid	bond	
stabilized	by	alanine	(Ala).	(d)	Generation	of	salt	bridge	between	glutamine	and	free	amine	of	
cleaved	substrate.	Modified	from	Rossello	et	al.	2009.56		
a b
cd
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The	subpockets	of	MMPs	located	on	either	side	of	the	active	site	give	the	selectivity	for	given	
substrates	and	account	for	the	differences	between	MMPs.	The	subpockets	on	the	‘left’	side	of	
the	active	site	are	designated	S3,	S2,	and	S1.54	The	subpockets	on	the	‘right’	side	are	‘primed’,		
labelled	as	S3’,	S2’,	and	S1’.54	The	greatest	difference	in	the	subpockets	is	between	the	S1’	
subpockets	of	the	MMPs,	varying	in	the	amino	acid	residues	and	the	depth.54	The	S1’	subpocket	
can	be	divided	based	on	the	depth,	with	MMP-1	and	MMP-7	having	a	shallow	S1’	subpocket;	
MMP-2,	-8,	and	-9	having	an	intermediate	depth;	and	MMP-3,	-11,	-12,	-13,	and	-14	having	a	
deep	S1’	subpocket.54		
1.4	Matrix	Metalloproteinases	in	Cancer	
The	MMPs	have	diverse	roles	in	cancer	development	and	progression.	Not	only	can	MMPs	be	
expressed	by	tumor	cells,	but	they	have	also	been	found	to	be	expressed	by	the	stromal	cells	in	
the	surrounding	area,	which	shows	that	MMPs	have	a	greater	role	in	cancer	progression	than	
just	 their	 ability	 to	 degrade	 the	 ECM.54	 MMPs	 have	 the	 ability	 to	 degrade	 cell-adhesion	
molecules,	 modulate	 both	 cell-cell	 interactions	 and	 cell-ECM	 interactions	 leading	 to	 the	
progression	of	cancer.26	MMPs	have	been	associated	with	multiple	cancer	processes	including:	
cancer	 cell	 proliferation,	 tumor	 angiogenesis	 and	 vasculogenesis,	 cancer	 cell	 invasion	 and	
migration.		
	 In	the	early	stages	of	tumorigenesis	MMPs	have	been	shown	to	contribute	to	the	tumor	
microenvironment	promoting	cell	proliferation.55	MMPs	have	the	ability	to	activate	growth	
factors	that	induce	cancer	cell	proliferation.55	In	addition,	MMP-1,	2,	3,	7,	9,	11,		and	19,	can	
cleave	IGF	(insulin-like	growth	factors)-binding	proteins	that	regulate	availability	of	growth	
	 25	
factors	such	as	epidermal	growth	factor	receptor,	further	facilitating	cancer	cell	proliferation.26	
The	degradation	of	the	ECM	must	also	occur	in	order	to	generate	pro-angiogenic	factors	that	
contribute	to	angiogenesis	and	vasculogenesis.26	It	has	been	shown	that	MMP-2,	-9	and	MMP-	
14	are	the	main	MMPs	involved	in	angiogenesis,	but	MMP-1	and	-7	also	play	a	role.26	
Specifically	MMP-9	promotes	angiogenesis	because	it	increases	the	availability	of	vascular	
endothelial	growth	factor	(VEGF),	an	important	factor	in	tumor	vasculature.26		
	 Cancer	cell	invasion	and	migration	is	capable	due	to	the	proteolytic	ability	of	MMPs	to	
regulate	cell-cell	and	cell-ECM	interactions.26	Both	MMP-2	and	MMP-9	have	been	shown	to	
degrade	multiple	components	of	the	ECM	allowing	for	cancer	cell	invasion.26	The	over	
expression	of	MMP-2,	-3,	-9,	-13,	-14	have	been	shown	to	allow	for	epithelial	cell	to	
mesenchymal	cell	transition,	with	mesenchymal	cells	having	the	increased	ability	to	migrate.26	
	 In	a	study	of	12	malignant	human	glioma	cell	lines,	supernatant	MMP-3	was	expressed	
in	the	LN-18	and	highly	expressed	in	the	U87MG	cell	line.57	The	U87MG	cell	line	was	the	most	
migratory	cell	line	and	one	of	the	most	invasive.57	In	rat	9L	glioma	cells,	the	micro-RNA	miR-152	
inhibited	invasion	through	MMP-3.58	While	there	are	links	of	MMP-3	to	glioma	invasiveness,	
more	research	is	still	needed.	
1.5 A	Summary:	Hypothesis,	Objectives	and	Aims	
As	a	possible	target	for	therapeutic	design,	the	functions	of	MMP-3	in	GBM	progression	are	
poorly	understood.	The	overall	hypothesis	of	this	work	is	that	MMP-3	is	a	key	regulator	of	
aggressive	behavior	in	high	grade	glioma	cells.		Aim	1:	We	first	validate	the	expression	and	
activity	of	this	protein	in	the	connexin43	model	of	GBM	migration/invasion59	(Chapter	2)	and	
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demonstrate	upregulation	of	MMP-3	in	high	motility	C6	glioma.	Proteomic	MMP-3	expression	
data	was	further	supported	by	the	use	of	Western	Blot.	A	fluorescence	NFF-3	protocol	was	
established	to	determine	MMP-3	activity.	Using	this	cellular	model	and	assays,	Aim	2:	we	
monitor	the	performance	of	commercial	and	novel	chemically	synthesized	(peptidomimetics)	
inhibitors	of	MMP-3	(Chapter	3).	The	design	of	the	inhibitors	was	based	upon	the	active	
site/subsites	of	MMPs	and	the	backbone	of	the	broad	spectrum	MMP	inhibitor	Ilomastat.	The	
sulfonyl	binding	groups	were	designed	based	on	potential	chelating	to	the	catalytic	zinc	ion	of	
MMP3.	Overall,	seven	potential	compounds	were	proposed.	In	addition	to	Ilomastat,	three	
compounds	were	synthesized	and	tested.	Aim	3:	Monitor	inhibition	of	MMP-3	effects	its	
activity	and	migration	ability	of	C6-13	cells	(Chapter	4).	Here,	the	inhibitory	effect	of	ilomastat	
on	MMP-3	was	monitored	through	the	NNF-3	assay	to	determine	ilomastat	concentration	on	
the	inhibition	of	MMP-3.	Propidium	iodide	flow	cytometry	to	determine	the	amount	of	cell	
death	upon	ilomastat	exposure.	Zymography	was	performed	to	analyze	the	effect	of	ilomastat	
on	the	expression	and	activity	of	MMP3.	Scratch	wound	assay	was	performed	to	determine	the	
effect	of	ilomastat	inhibition	on	cell	migration.	
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Chapter	2:	MMP-3	Expression	&	Activity	in	C6	and	C6-13	Cell	Lines	
2.1	Introduction	
MMP-3	(Stromelysin	1)	belongs	to	the	stromelysin	category	of	MMPs	as	it	is	a	stromal	MMP,	
with	the	same	domain	organization	as	other	stromelysins.	The	domain	organization	of	MMP-3	
consists	of	a	signal	domain	(for	secretion	into	extracellular	space),	propeptide	domain	(cleaved	
to	activate	MMP-3),	catalytic	domain	containing	the	catalytic	zinc	ion,	a	hinge/linker	region	to	
join	the	catalytic	domain	to	the	hemopexin	C-terminal	domain,	which	contributes	to	substrate	
specificity	(Figure	2.1.2).55				
	
Figure	2.1.1:	MMP-3	domains.	Adapted	from	Overall	et	al.	2002.55	
	
MMP-3	has	numerous	substrates	including	ECM	substrates;	collagen,	fibronectin,	gelatin,	
laminin	(Table	2.1.1).	An	important	role	of	MMP-3	is	its	ability	to	activate	pro-MMPs	(Table	
2.1.1),	leading	to	more	active	MMPs,	more	ECM	degradation,	making	MMP-3	crucial	to	ECM	
remodeling.	As	noted	in	Chapter	1,	ECM	degradation	plays	a	key	role	in	the	migration	and	
Zn2+
Signal	Peptide
Propeptide
Catalytic	Domain
Hinge/linker
Hemopexin C-terminal	domain
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invasion	potential	of	GBM.	In	addition,	MMP-3	expression	has	been	shown	to	potentially	have	a	
link	to	the	invasiveness	of	GBM.	The	C6/C6-13	rat	glioma	cells	can	be	used	as	a	model	to	study	
the	link	between	MMP-3	expression	and	GBM	ivasiveness.	
	
Table	2.1.1:	Matrix	Metalloproteinase	3	extracellular	matrix	substrates,	non-matrix	
substrates,	and	cellular	sources	of	MMP-3.60		
Extracellular	Matrix	
Substrates	
Non-Matrix	Substrates	 Cellular	Sources	of	MMP-3	
Aggrecan,	Biglycan,	Collagen	
Telopeptides,	Collagens	(Type	III,	
IV,	V,	VII,	IX,	X,	and	XI)	non-triple	
helical	regions,	Decorin,	Elastin,	
Entactin,	Fibrin,	Fibrinogen,	
Fibronectin,	Fibulin,	Gelatin,	
Laminin,	Link	Protein,	Myelin	Basic	
Protein,	Osteonectin,	Perlecan,	
SPARC,	Tenasin,	Versican,	
Vitronectin		
a1-Anti-Chymotrypsin,	a2-
Antiplasmin,	Carboxymethylated	
transferrin	(Cm-Tf),	Casein,	
Decorin,	E-cadherin,	endothelial	
growth	factor	(EGF),	IGFBP-3,	L-
selectin,	a2-Macroglobulin,	
Osteopontin,	Plasminogen,	Pro-
MMP1,	Pro-MMP3,	Pro-MMP7,	
Pro-MMP8,	Pro-MMP9,	Pro-
MMP13,	urokinase-type	
Plasminogen	Activator	(uPA),	
vascular	endothelial	growth	factor	
Endothelial	cells,	Smooth	muscle	
cells,	Lymphocytes,	Macrophages	
	
	
The	C6	cell	line	was	produced	by	administering	N-nitrosomethylurea	to	outbred	Wistar	rats	
over	the	course	of	8	months.61,62	The	excised	and	tissue	cultured	tumor	designated	as	“#6”	was	
cloned	by	Benda	et	al.	and	subsequently	designated	as	C6.62	The	C6	cell	line	is	a	glial	tumor	cell	
line	with	mutant	p16/Cdkn2a/Ink41	locus	and	wildtype	p53.63	The	genetic	changes	that	
occurred	within	the	C6	cell	line	are	the	most	similar	to	those	that	occur	in	human	brain	
tumors.64	Some	frequently	overexpressed	genes	in	human	GBM	include	PDGFb,	IGF-1,	EGFR,	
Erb3/Her3	which	also	show	increased	expression	in	the	C6	cell	line.65	In	addition	to	the	C6	cell	
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line,	C6	cells	exogenously	expressing	high	levels	of	connexin43	(Cx43)	were	used.59	Referred	to	
as	C6-13,	cells	with	increased	Cx43	have	been	shown	to	express	higher	levels	of	proteins	
associated	with	migration	and	invasion.66		
A	notable	difference	between	the	C6	cells	and	the	C6-13	cells,	is	the	change	in	mobility	
that	occurs	with	the	overexpression	of	Cx43.	The	C6-13	cell	line	has	an	increase	in	migration	in	
comparison	to	the	C6	cell	line.	In	a	scratch	wound	experiment	performed	by	Aftab	et	al.	2018	
(in	review),	there	was	a	noticeable	difference	in	the	relative	migration	between	the	C6	and	C6-
13	cells	(Figure	2.1.1	A),	with	the	C6	cells	filling	the	scratch	by	proliferation	(dense	
concentration	of	cells	indicating	proliferation)	and	the	C6-13	cells	migrating	into	the	scratch	
(Figure	2.1.1	C	&	D).	In	addition,	when	conditioned	media	(CM)	from	the	C6-13	cells	was	applied	
to	C6	cells,	migration	increased	(Figure	2.1.1	A).	However,	when	C6	CM	was	applied	to	C6-13	
cells	there	was	no	change	in	migration.	This	increase	in	migration	must	be	due	to	the	
differential	regulation	of	secreted	proteins	by	the	C6-13	cell	line,	which	includes	the	
upregulation	of	proteins	associated	with	GBM	migration	and	invasion	such	as	MMP-3,	
osteopontin,	and	collagens	(Figure	2.1.1).	An	increase	mechanical	tension	provided	by	the	
upregulation	of	multiple	ECM	proteins	supports	an	environment	in	which	migration	occurs	at	a	
greater	rate.			
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Figure	2.1.2:	Scratch	wound	assay	and	secretome	changes	in	C6	versus	C6-13	cells.	(A)	Relative	
migration	of	C6	cells,	C6	cells	with	C6-13	CM	applied,	C6-13	cells,	and	C6-13	cells	with	C6	CM	
applied	shows	that	proteins	associated	with	migration	are	secreted	by	C6-13	cells.	(B)	Cell	
death	was	the	same	for	C6	and	C6-13	cells.	(C	&	D)	Scratch	wound	assay	showing	migration	of	
C6-13	and	C6	cells	after	4	hours.	Table	at	the	bottom	shows	the	top	upregulated	proteins	in	the	
C6-13	cells	compared	to	the	C6	cells.	Figures	taken	with	permission	from	Mesnil	et	al.	2019.67	
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2.1.1	Methods	to	study	MMPs	
While	it	has	been	shown	that	the	overall	quantity	of	MMP-3	is	upregulated	in	the	C6-13	cells,	it	
is	unknown	if	this	increase	in	expression	is	linked	to	the	enzymatic	activity	of	MMP-3.	To	further	
understand	the	enzymatic	activity	of	MMP-3	in	the	conditioned	media	and	how	the	addition	of	
inhibitors	effects	MMP-3,	a	fluorogenic	peptide	substrate	assay	was	performed.	This	enzyme	
assay	is	useful	because	low	concentrations	may	be	used	and	the	fluorescence	may	be	
monitored	continuously.	The	three	types	of	fluorogenic	substrates	used	are,	aromatic	amines,	
contact-quenched,	and	resonance	energy	transfer	quenched.	(Fluorometric	assays	of	
proteolytic	enzymes).		A	common	resonance	energy	transfer	fluorophore	and	quencher	
combination	is	(7-methoxycoumarin-4-yl)acetyl	(Mca)	and	N-2,4-dinitrophenyl	(DnP).	In	this	
combination	of	Mca	and	Dnp,	the	Dnp	absorption	spectrum	overlaps	the	Mca	fluorescence	
emission	spectrum,	essentially	masking	the	fluorescence	of	the	Mca.68	Once	the	peptide	is	
cleaved,	the	Dnp	no	longer	masks	the	fluorescence	of	the	Mca	(Figure	5.1),	and	the	amount	of	
fluorescence	measured	is	relative	to	the	amount	of	peptide	cleaved.		A	fluorogenic	peptide	that	
contains	Mca	at	subsite	P6	and	Lys(Dnp)	at	subsite	P5’	can	be	used	to	detect	enzymatic	
activity.69	The	NFF-3	[Mca-Arg-Pro-Lys-Pro-Val-Glu~Nva-Trp-Agr-Lys(Dnp)-NH2]	probe	
developed	by	Nagase	et	al.	is	very	slowly	hydrolyzed	by	the	collagenase	MMP-9	(kcat/Km:	10	100	
s-1M-1)	and	rapidly	by	MMP-3	(kcat/Km:	218	000	s-1M-1)	.69,70		This	makes	the	NFF-3	substrate	
ideal	for	determining	the	activity	of	MMP-3.		
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Figure	2.1.3:	Mechanism	behind	fluorogenic	substrates.	The	fluorophore	(Mca)	and	quencher	
(Dnp)	are	connected	through	an	amino	acid	sequence	that	acts	as	a	substrate	for	a	given	MMP.	
When	connected	the	Dnp	absorbs	the	fluorescence	of	the	Mca	through	fluorescence	resonance	
energy	transfer.	Once	cleaved	by	the	MMP,	the	fluorescence	of	the	Mca	is	no	longer	absorbed	
by	the	Dnp,	and	the	relative	absorbance	can	be	measured.		
	
C6-13	cells	have	an	increase	in	migration	compared	to	their	C6	counterparts.	This	increase	in	
migration	may	be	due	to	the	fact	that	MMP-3,	an	ECM	protease	which	aids	in	migration,	is	the	
most	upregulated	secretome	protein.67	To	verify	that	MMP-3	is	upregulated	in	the	C6-13	cells,	I	
performed	a	label	free	mass	spectrometry	experiment	of	C6	versus	C6-13	cells	to	identify	if	
MMP-3	was	upregulated.	Western	blot	was	used	to	further	confirm	that	MMP-3	is	upregulated	
in	the	C6-13	cells.	Finally,	the	NFF-3	assay	was	developed	to	determine	activity	of	MMP-3	in	the	
C6-13	cells.	
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2.2	Materials	&	Methods	
	
2.2.1	C6	Glioma	Culture	&	Protein	Precipitation	
Rat	glioblastoma	cells	(C6	and	C6-13)	were	cultured	in	4.5g/L	glucose	medium	with	10%	fetal	
bovine	serum	(FBS),	with	1%	antibiotics.	Cells	were	incubated	at	37°C	with	4.0%	CO2.		At	80-
90%	confluence,	cells	were	aspirated,	washed	with	PBS	twice,	washed	with	serum	free	media	
and	were	conditioned	with	serum	free	media	for	24	hours.	After	24	hours,	the	media	was	
removed	and	the	proteins	were	precipitated	with	ethanol	followed	by	determining	the	protein	
concentration	and	in-solution	digestion	(trypsin)	for	LC-MS/MS.		
	
2.2.2	Bicinchoninic	Acid	(BCA)	Protein	Assay	
Protein	concentration	in	each	sample	was	determined	using	the	bicinchoninic	acid	protein	
assay.	BCA	working	reagent	(WR)	was	prepared	by	mixing	50	parts	reagent	A	to	48	parts	
reagent	B	to	2	parts	reagent	C.	Into	the	wells	of	a	96-well	plate,	200	µL	of	WR	was	added,	
followed	by	25	µL	of	protein	sample	(sample	may	be	diluted).	The	plate	was	then	incubated	at	
37°C	for	30	minutes.	After	the	incubation	period,	the	absorbance	of	each	well	was	measured	by	
spectrometer	using	the	BCA	Protein	Quantification	protocol	from	SoftMax	Pro	7	software.	A	
standard	curve	was	initially	constructed	by	measuring	the	absorbance	of	known	concentrations	
of	bovine	serum	albumin	(BSA).	Protein	sample	concentrations	were	then	calculated	by	placing	
the	measured	absorbance	into	the	standard	curve	equation.		
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2.2.3	Peptide	Sample	Preparation	and	Analysis		
Equal	amounts	of	C6	and	C6-13	peptides	were	separated	by	a	C18	stage	tip,	then	analyzed	using	
nanoHPLC-MS/MS	(Agilent	1200)	on	an	accurate	mass	QTOF	mass	spectrometer	(Agilent,	6530).	
Peptides	were	identified	using	Mascot	Server	(Matrix	Science,	UK).	The	following	parameters	
were	used	for	liquid	chromatography,	mass	spectrometry,	and	the	Mascot	search.	
Table	2.2.1:	Liquid	Chromatography,	Mass	Spectrometry,	and	Mascot	Search	Parameters	
Liquid	Chromatography	Parameters	
Column	
	
Injection	Volume	
Wash	Solvent	
Flow	Rate	
10cm	vented	trap	column	and	3.0µm	C18	column	(Dr.	Maisch	
reprosil-pur	20cm	×	100µm) 
5.00µL	
Acetonitrile	
300	nL/min	
Mass	Spectrometry	Parameters	
Ion	Source	
Polarity	mode	
Mass	range	(max)	
Active	exclusion	
Charged	state	preference	
Nano	Spray	
Positive	
2000	(m/z)	
On,	3	spectra	for	3	min	
2,	3	
Mascot	Search	Parameters	
Taxonomy	
Enzyme	
Fixed	Modifications	
Variable	Modifications	
Peptide	mass	tolerance	
Fragment	mass	tolerance	
Peptide	charge	
Instrument	
Uniprot	Rattus	
semiTrypsin	
Carbamidomethyl	(C)	
Gln	àpyro-Glu	(N-term	Q),	Oxidation	(M)	
±20	ppm	
±0.6	Da	
2+	and	3+	
ESI-QUAD-TOF	
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2.2.4	Western	Blot	
Cells	were	plated	on	a	six	well	plate	at	a	concentration	of	200,000	cells	per	well.	Cells	were	
grown	to	confluence	(3-4	days)	and	conditioned	with	serum	free	DMEM	media	for	24	hours.	
After	24	hours,	the	conditioned	media	was	collected	in	chilled	15mL	falcon	tubes	and	
immediately	placed	on	ice.	Ice	cold	acetone	(-20°C)	was	added	to	the	media,	1	part	conditioned	
media	to	4	parts	acetone.	Tubes	were	incubated	for	1	hour	in	a	-20°C	freezer.	Proteins	were	
pelleted	by	centrifuging	for	12	minutes	at	4800g	in	pre-chilled	rotors.	Supernatant	was	
removed	and	proteins	were	suspended	in	2x	loading	buffer	without	DTT.	Proteins	were	
incubated	at	room	temperature,	lightly	vortexed,	incubated	for	a	further	20	minutes.	At	this	
time	2	µL	of	sample	was	removed	and	diluted	in	28	µL	of	distilled	water	(15x	dilution)	for	BCA	
analysis.	DTT	was	added	for	a	final	concentration	of	0.1M	and	samples	boiled.	Protein	samples	
were	loaded	on	a	10%	SDS	gel	and	ran	at	125V	for	approximately	3	hours.	Proteins	were	then	
transferred	to	the	membrane	ran	at	30V	for	3	hours	at	4°C.		Membrane	was	then	washed	in	
blocking	buffer	(5%	nonfat	dried	milk	in	TBST	(tris-buffered	saline	with	tween	20))	for	1	hour.	
After	the	blocking	step,	membrane	was	incubated	at	4°C	in	1:1000	primary	antibody	(MMP-3	
rabbit	antibody)	to	1%	nonfat	dried	milk	in	TBST	for	24	hours.	After	incubation,	the	membrane	
was	washed	three	times	with	TBST	for	5	minutes	each	at	room	temperature.	Membrane	was	
then	washed	for	1.5	–	2	hours	with	secondary	rabbit	antibody	(1:2000	secondary	antibody	to	
1%	milk	in	TBST).	The	membrane	was	washed	three	times	with	TBST	for	5	minutes	at	room	
temperature,	then	stained	using	ECL	(enhanced	chemiluminescence)	stain	for	1	–	2	minutes.	
Membrane	was	analyzed	using	a	scanner	to	detect	the	signal	from	the	ECL	stain.	A	digital	image	
of	the	membrane	showing	protein	bands	was	generated	and	ImageJ	was	used	for	band	analysis.		
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2.2.5	ImageJ	Analysis	
ImageJ	software	was	used	for	both	western	blot	analysis.	Images	in	jpeg	format	were	uploaded	
and	changed	to	an	8-bit	(black	and	white)	image.	Bands	were	selected	using	the	rectangle	
selection	tool,	with	the	rectangle	being	twice	as	high	than	it	is	wide.	The	first	lane	(band)	is	
selected	under	the	“gels”	section	(“select	first	line”)	of	the	“analyze”	tab.	A	new	rectangle	is	
then	generated	and	can	be	positioned	over	the	next	band,	this	band	then	selected	under	the	
“gels”	section,	“select	next	lane”.	Band	selection	is	continued	until	all	bands	have	been	
selected.	The	lanes	(bands)	can	then	be	plotted	using	the	“plot	lanes”	option	in	the	“gels”	
section,	generating	peaks	for	each	band.	The	wand	tool	is	used	to	select	inside	the	peak	and	the	
area	of	the	peak	is	generated	by	selecting	“label	peaks”	from	the	“gels”	section.	The	area	of	the	
peak,	and	thus	the	area	of	the	band	corresponds	to	the	relative	amount	of	MMP-3	present.		
	
2.2.6	NFF-3	Fluorescence	Assay	
The	NFF-3	probe	is	from	Cayman	Chemical	(³95%	pure,	MW:	1675.8)	with	the	formal	name:	N2-
[2-(7-methoxy-2-oxo-2H-1-benzopyran-4-yl)acetyl]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-valyl-L-a-
glutamyl-L-norvalyl-L-tryptophyl-L-arginyl-N6-(2,4-dinitrophenyl)-L-lysinamide.	Cells	were	plated	
on	a	six	well	plate	at	a	concentration	of	200,000	cells	per	well.	Cells	were	grown	to	confluence	
(3-4	days)	and	conditioned	with	serum	free,	phenol	red	free	media	for	24	hours.	After	
conditioning,	the	media	was	collected.	Each	experimental	condition	had	its	own	control	
condition.	Using	a	96	well	plate	15µL	of	distilled	water	were	added	to	the	control	wells	and	
15µL	of	100µM	NFF-3	were	added	to	the	experimental	well.	Then	300µL	of	the	conditioned	
media	(C6WT,	C613,	and	DMEM	media)	were	added	to	the	control	and	experimental	wells,	
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resulting	in	an	overall	concentration	of	4.76µM	NFF-3.	The	excitation	wavelength	of	the	
spectrometer	was	set	to	325nm	while	the	emission	was	set	to	393nm.	The	fluorescence	was	
measured	every	ten	minutes	over	the	course	of	six	hours,	with	the	plate	shaking	for	15	seconds	
before	each	reading.	The	experiment	was	conducted	at	37°C.		
	
2.3	Results	&	Discussion	
2.3.1	Secretome	Analysis	of	C6	and	C6-13	Cells	
Initially	a	label	free	analysis	of	the	secretome	of	C6	versus	C6-13	cells	was	performed	to	verify	
that	MMP-3	is	in	fact	upregulated	in	the	C6-13	cells.	MMP-3	peptides	were	identified	from	the	
conditioned	media.	In	Figure	2.3.1,	a	difference	in	the	chromatographic	(XIC)	peak	area	of	the	
MMP-3	peptide	SANAEALMYPVYK	from	the	C6	secretome	to	the	C6-13	secretome	can	be	seen.	
Peak	areas	were	generated	using	Skyline.	While	this	is	only	N=1,	there	is	a	notable	visual	
difference	between	the	peak	of	the	MMP-3	peptide	in	the	C6	and	the	C6-13.	There	is	no	visible	
peak	in	the	C6	secretome,	indicating	that	the	relative	amount	of	MMP-3	is	undetectable	from	
the	baseline,	whereas	in	the	C6-13	there	are	clear	peaks	in	the	precursor	ion	and	[M+2H]2+	ion	
at	the	retention	time	of	84.0	minutes,	which	corresponds	to	the	retention	time	of	the	
SANAEALMYPVYK	peptide.	This	secretome	analysis	confirms	that	MMP-3	is	upregulated	in	the	
C6-13	as	found	in	the	Mesnil	et	al.	2019	study.	
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Figure	2.3.1:	Comparison	of	MMP-3	chromatographic	(XIC)	peak	areas	of	peptide	
SANAEALMYPVYK	(retention	time	84.0)	from	secretome	of	C6	&	C6-13.	 
	
	
2.3.2	Western	Blot	of	C6	and	C6-13	
Western	blot	analysis	was	performed	to	further	verify	the	upregulation	of	MMP-3	in	C6-13	
cells.	MMP-3	has	a	molecular	weight	of	54	kDa	(Figure	2.3.2	a).	From	Figure	2.3.2	a	it	is	clearly	
visible	that	MMP-3	is	significantly	upregulated	in	the	C6-13	as	opposed	to	the	C6	where	no	
detectable	band	is	present.	From	ImageJ	analysis,	quantified	area	of	the	C6-13	bands	is	
statistically	significantly	greater	than	that	of	the	C6	bands	(Figure	2.3.2	b).	This	western	blot	
data	supports	the	mass	spectrometry	data	in	which	C6-13	cells	express	higher	levels	of	MMP-3	
than	the	C6	cells.		
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Figure	2.3.2:	Western	blot	analysis	of	MMP-3	in	C6	and	C6-13	secretome.	(a)	Detection	of	
MMP-3	in	C6-13	versus	C6	(N=3).	(b)	Normalized	area	of	the	detected	bands	by	Western	blot	
showing	a	statistically	significant	difference	between	the	C6	and	C6-13.	Bands	normalized	to	C6	
area.		
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2.3.3	C6	and	C6-13	NFF-3	Fluorescence	Assay	
Knowing	that	the	overall	expression	of	MMP-3	is	upregulated	from	the	C6	cells	to	the	C6-13	
cells,	next	we	wanted	to	determine	if	there	is	a	correlation	between	expression	and	activity.	If	
increased	expression	corresponds	to	increased	activity,	it	would	further	emphasize	the	use	of	
C6-13	cells	as	a	model	to	study	MMP-3.	To	test	the	activity	of	MMP-3,	the	NFF-3	assay	was	
utilized.		
The	majority	of	NFF-3	assays	are	used	on	the	MMP-3	protein	itself	or	on	whole	cells	
lysates.	However,	it	would	be	difficult	to	isolate	MMP-3	from	the	conditioned	media	and	we	are	
only	concerned	with	MMP-3	in	the	conditioned	media,	not	in	the	cells.	Therefore,	we	designed	
an	NFF-3	assay	to	be	used	on	the	conditioned	media	itself.	The	NFF-3	substrate	concentration	
was	set	at	4.76	µM,	which	is	in	the	recommended	range	of	2.5	–	75	µM.71	A	time	point	of	six	
hours	was	set,	due	to	the	leveling	off	of	fluorescence	around	this	time.		
This	study	was	designed	to	have	three	conditions:	the	control;	unconditioned	DMEM	
media,	and	two	experimental;	conditioned	C6	media	and	C6-13	conditioned	media.	There	was	
no	change	in	the	relative	fluorescence	of	the	unconditioned	DMEM	media	(Figure	2.3.3).		If	
increased	expression	correspond	to	activity,	then	a	significant	change	in	RFU	over	time	should	
be	apparent	for	the		C6-13	condition	based	upon	the	Western	data.	From	the	NFF-3	data,	the	
C6-13	conditioned	media	does	have	significantly	higher	MMP-3	activity	than	the	C6	(Figure	
2.3.3).	Therefore,	not	only	do	the	C6-13	cells	have	a	higher	expression	of	MMP-3,	but	also	
higher	activity.	
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Figure	2.3.3:	NFF-3	assay	of	MMP-3	activity	in	C6	and	C6-13	secretome.	The	change	in	relative	
fluorescence	units	was	measured	over	the	course	of	six	hours	and	plotted	for	the	conditions:	
unconditioned	DMEM	media,	C6	CM,	and	C6-13	CM.		
	
2.4	Conclusion	
	 The	mass	spectrometry	secretome	analysis	of	C6	versus	C6-13	cells	performed	indicated	
that	MMP-3	is	upregulated	in	C6-13	cells.	Western	blot	analysis	provided	further	confirmation	
that	the	expression	of	MMP-3	is	upregulated	in	C6-13	and	validated	the	mass	spectrometry	
data.	Not	only	is	the	expression	of	MMP-3	upregulated,	but	from	the	NFF-3	assay,	the	activity	
of	MMP-3	is	also	upregulated.	The	increased	expression	and	activity	of	MMP-3	in	the	C6-13	
cells,	provides	a	model	to	study	the	link	between	MMP-3	and	invasiveness.		
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Chapter	3:	Synthesis	of	Matrix	Metalloproteinase	3	Inhibitors	
3.1	Introduction	
Inhibiting	MMPs	may	negate	some	of	the	invasiveness	of	GBM.	Currently,	various	inhibitors	for	
MMPs	have	been	designed	based	on	the	catalytic	zinc	ion	in	the	active	site	and	the	subpockets	
of	the	MMPs.	The	majority	of	the	MMP	inhibitors	to	date	that	have	been	developed	are	
peptidomimetics.	The	idea	of	using	endogenous	peptides	as	therapeutics	began	in	the	1920’s,	
purified	insulin	from	bovine	pancreas	was	used	to	treat	diabetes.	Use	of	peptides	as	a	
therapeutic	option	over	small	molecules	was	initially	difficult	due	to	challenges	faced	with	
peptide	synthesis,	including	low	yields,	reduced	purity,	poor	stability	of	the	peptides,	and	the	
delivery	method.72	Generally	peptides	are	unstable,	have	poor	oral	bioavailability,	low	
membrane	permeability,	and	linear	peptides	have	short	half-lives	that	may	reduce	the	dosage	
that	reaches	the	target.72	Thus	the	limitations	that	accompany	peptides,	may	be	overcome	by	
using	peptidomimetics.72	Peptidomimetics	are	any	small	molecules	that	are	modified	from	an	
existing	peptide,	or	mimics	the	structure	of	a	peptide.73	Peptidomimetics	may	be	better	
therapeutic	compounds	compared	to	small	molecule	compounds	and	antibodies	due	to	their	
similarity	to	endogenous	substrates.72	This	similarity	can	be	exploited	to	interfere	with	protein-
protein	interactions	and	modulate	protein	signaling.74	In	addition,	peptide-based	therapeutics	
can	be	synthesized	in	larger	quantities,	generally	are	non-immunogenic,	usually	do	not	have	
tertiary	or	quaternary	structures	(as	with	antibodies)	making	them	more	stable,	and	have	
greater	specificity	for	the	protein	target	over	their	antibody	counterparts.74		
In	HER2-positive	breast	cancer,	monoclonal	or	combination	antibodies,	alongside	
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chemotherapy	is	the	traditional	treatment	route.75	Kanthala	et	al.	have	shown	that	
peptidomimetic	compounds	can	inhibit	the	protein-protein	interaction	of	HER2:HER3,	having	
antiproliferative	activity,	without	the	limitations	of	antibody	treatment.75		In	approximately	50%	
of	invasive	prostate	cancers,	the	androgen-regulate	promoter	TMPRSS2	is	fused	to	the	coding	
region	of	ERG.76	ERG	derived	peptides	and	peptidomimetics	destabilize	the	ERG	interaction,	
decreasing	invasion	and	metastasis.76		While	peptidomimetic	MMP	inhibitors	have	not	been	
greatly	explored	in	cancer	treatment,	the	majority	of	MMP	inhibitors	designed	for	other	
diseases	have	utilized	the	peptidomimetic-based	strategy.		
	 MMPs	were	first	introduced	as	therapeutic	targets	over	30	years	ago.	The	goal	of	matrix	
metalloproteinase	inhibitors	(MMPIs)	was	to	control	the	synthesis,	regulation,	activation,	and	
enzyme	activity.26	The	first	generation	of	MMPIs	were	peptidomimetics,	mimicking	the	
structure	of	collagen	at	cleavage	site	of	MMP.26	Collagenases	preferentially	cleave	N-terminal	
to	hydrophobic	side	chains,	such	as	leucine,	with	the	leucine	residing	in	the	S1’	subsite	to	the	
right	if	the	catalytic	zinc	ion.77	In	a	study	of	7	MMPs	(MMP-1,2,3,7,8,9,1),	collagen	was	most	
frequently	cleaved	at	the	N-terminal	end	of	leucine.78	These	first	generation	MMPIs	were	
designed	as	a	competitive	inhibitor,	chelating	to	the	catalytic	zinc	ion	by	using	the	hydroxamic	
acid	zinc	binding	group	(ZBG).26,54	As	more	MMPs	were	identified	and	the	structure	of	MMPs	
was	determined	using	crystallographic	methods	and	X-ray	diffraction,	second	and	third	
generation	MMPIs	were	developed.54	
All	MMPIs	that	have	been	developed	share	two	general	characteristics:	a	ZBG	and	a	side	
chain	that	interacts	with	MMP	subpockets	surrounding	the	zinc	ion.49	The	MMPI	design	
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generally	includes	a	ZBG,	because	the	catalytic	zinc	ion	in	the	MMP	active	site	facilitates	the	
cleavage	of	substrates.54	The	zinc	bound	water	molecule	in	the	active	site	is	responsible	for	
cleaving	peptide	bonds	(Figure	1.3.3).	The	ZBG	is	used	to	displace	this	water	molecule,	
deactivating	the	enzyme.54	Additionally,	the	ZBG	helps	to	direct	side	chains	of	the	
peptidomimetic	backbone	into	the	subpockets	of	the	MMP,	furthering	its	inhibition.54	.	
The	first	generation	of	MMPIs	used	the	following	as	ZBGs:	hydroxamic	acids,	
carboxylates,	thiols,	and	phosphoric	acids.54	However,	the	hydroxamic	acids	as	a	ZBG	were	
favoured	because	of	their	ability	to	chelate	well	to	the	Zn2+	ion	forming	a	trigonal-bipyramidal	
geometry	around	the	Zn2+	and	their	simple	synthesis.54,48	Good	chelation	to	the	zinc	ion	was	
aided	by	the	fact	that	the	NH	group	and	deprotonated	OH	group	of	the	hydroxamic	acid	were	
able	to	hydrogen	bond	to	the	alanine	and	glutamic	acid	residues	in	the	active	site	(Figure	
3.1.1).54	
	
Figure	3.1.1:	Interaction	of	Batimastat	with	the	MMP	active	site.	Diagram	shows	the	bidentate	
binding	of	the	hydroxamic	acid	to	the	zinc	ion,	as	well	as	the	hydrogen	bonding	to	the	alanine	
and	glutamic	acid	residues	of	the	active.	This	binding	directs	the	peptide	backbone	and	side	
chain	into	the	S1’,	S2’,	and	S3’	subsites.	Modified	from	Jacobsen	et	al.	2010.54		
S1’
S2’
S3’
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The	first	MMPI	to	enter	clinical	trials	was	batimastat,	a	collagen-based	hydroxamic	acid	
peptidomimetic.26	Other	peptiomimetic	hydroxamates	include	marimastat	and	ilomastat.	
Batimastat	was	the	first	broad	spectrum	MMPI	to	enter	clinical	trials	in	patients	with	malignant	
ascites	and	malignant	pleural	effusion,	inhibiting	the	activity	of	most	major	MMPs	such	as	
MMP-1,	-2,	-3,	-7,	and	-9.27,50	The	hydroxamate	chelates	to	the	zinc	ion,	while	the	leucine	side	
chain	occupies	the	S1’	site	(Figure	3.1.1).47	Preclinical	studies	showed	that	Batimastat	had	good	
potential	as	an	anti-cancer	agent.48	However,	the	compound	was	almost	completely	insoluble,	
had	poor	oral	bioavailability	and	had	to	be	administered	directly	into	body	cavities	or	
intravenously.50	
	 Marimastat	is	another	broad-spectrum	inhibitor	that	has	better	oral	bioavailability	than	
Batimastat.27	When	Marimastat	was	used	in	combination	with	temozolomide	in	patients	with	
glioblastoma	multiforme,	there	was	an	improvement	in	progression-free	survival	at	six	months	
in	these	patients	and	an	overall	survival	of	45	weeks.55	In	addition,	Marimastat	had	positive	
results	in	patients	with	gastric	carcinoma	and	pancreatic	carcinoma.55	However,	it	was	
ineffective	at	doses	associated	with	musculoskeletal	toxicity.48	
Ilomastat	also	is	a	broad-spectrum	inhibitor	(inhibiting	MMP-1,	MMP-2,	MMP-3,	MMP-
7,	MMP-8,	MMP-9,	MMP-12,	MMP-14,	and	MMP-26)	that	uses	the	hydroxamic	acid	as	a	ZBG,	
with	a	backbone	consisting	of	the	amino	acids	leucine	and	tryptophan.79	Ilomastat	was	initially	
used	as	a	topical	treatment	for	corneal	ulcers.80	Although	Ilomastat	reached	phase	III	clinical	
trials,	it	also	has	the	poor	bioavailability	associated	with	hydroxamate	peptidomimetics.79 
Currently	no	hydroxamate-based	MMPI	have	been	approved	by	the	FDA.54	There	are	
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many	limitations	associated	with	hydroxamate-based	MMPIs	that	have	hindered	their	potential	
as	clinically	viable	compounds.	These	limits	include	low	oral	bioavailability,	poor	in	vivo	stability,	
and	undesired	side	effects,	such	as	musculoskeletal	pain	due	to	the	broad	spectrum	
inhibition.81	The	biggest	limitation	of	hydroxamate	MMPIs	is	that	drug	metabolism	can	lead	to	
ZBG	loss.48	The	first	MMPIs	were	developed	when	only	several	MMPs	were	identified	and	their	
structure	was	poorly	understood	due	to	the	lack	of	crystallographic	studies.	The	second	and	
third	generations	of	MMPIs	took	into	account	the	limitations	of	hydroxamate	ZBG	and	the	
structural	information	of	MMPs	from	crystallographic	studies.		
Second	and	third	generation	MMPIs	include	non-hydroxamate	and	reverse	hydroxamate	
(hydroxamate	group	is	substituted	on	nitrogen	instead	of	carbon)	ZBG	inhibitors	were	
developed	to	overcome	the	limitations	of	hydroxamate	inhibitors.48	Non-hydroxamate	and	
reverse	hydroxamate	ZBG	include:	carboxylates,	hydrocarboxylates,	sulhydryls,	phosphoric	
acid,	and	hydantoins.48	Non-hydroxamate	MMPIs	do	have	some	similarities	to	the	hydroxamate	
versions,	including	the	ability	to	form	five-member	chelates,	but	may	have	better	affinity	for	
the	catalytic	zinc	than	their	hydroxamate	counterparts.81	However,	there	is	still	an	issue	of	
broad	MMP	inhibition.			
To	reduce	broad	inhibition	that	occurs	with	MMPIs	due	to	the	structural	similarity	
between	MMPs,	it	may	be	more	effective	to	target	sites	such	as	the	S1’	subpocket,	that	are	less	
conserved	from	one	MMP	to	another.48	As	stated	before,	the	S1’	site	has	the	most	variation	
among	MMPs,	varying	in	both	depth	and	amino	acid	sequence.	Greater	selectivity	for	one	MMP	
over	another	may	be	accomplished	by	exploiting	variations	among	the	S1’	sites.		
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	 Ilomastat	was	chosen	as	the	compound	to	benchmark	further	derivatives	because	
ilomastat	has	been	shown	to	block	hypoxia-induced	invasion	in	breast	carcinoma.82	The	design	
of	these	derivatives	began	with	using	the	same	backbone	as	Ilomastat,	including	the	leucine	
residue	and	tryptophan	residue.	This	backbone	was	kept	the	same	because	MMP-3	has	a	
preference	for	leucine	in	the	S1’	subsite	and	aromatics	such	as	tryptophan	in	the	S2’	subsite.78	
The	tryptophan	residue	has	a	methylamine	at	the	C-terminal	end	as	opposed	to	a	carboxylic	
acid.	We	propose	using	sulfonyl	derivatives	as	the	zinc	binding	group	because	of	the	potential	
chelating	ability	of	sulfur	to	zinc.	This	stems	from	the	fact	that	the	sulfhydryl	group	of	the	
propeptide	domain	coordinates	to	the	zinc	in	the	inactive	zymogen	of	MMPs	(Figure	1.6.1).	In	
addition,	zinc/thiolate	coordination	is	generally	thermodynamically	stable.83	To	test	the	
thermodynamic	stability	of	each	compound,	in	silico	molecular	docking	was	utilized.		
	 In	silico	molecular	modelling	has	become	a	useful	tool	in	drug	discovery/development	
due	to	the	advances	in	computational	methods	and	increased	number	of	protein	structures	
deposited	in	the	Protein	Data	Bank	(PDB).84,85	Molecular	docking	can	be	applied	to	screen	for	
top	potential	drug	candidates,	thus	reducing	the	number	of	in	vitro	tests.85	A	molecular	docking	
algorithm	takes	the	receptor	(protein)	and	the	ligand	(compound)then	predicts	the	interactions	
that	may	occur,	specifically	whether	the	ligand	will	interact	with	the	receptor,	and	the	binding	
affinity.85	Binding	affinity	scores	are	obtained	using	an	energy	function,	which	approximates	the	
real	energy	value.85		
This	study	uses	MOE	(molecular	operating	environment)	as	the	in	silico	molecular	
docking	software.	MOE	gives	binding	energy	scores	based	on	the	strength	of	binding	
interactions	that	exist	between	the	compound	and	active	site	of	MMP-3.	The	software	also	
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indicates	the	types	of	molecular	interactions	that	occur	between	the	compound	and	active	site,	
such	as	electronegative	interactions,	pi	bonding,	hydrogen	bonding.		
	
3.2	Materials	&	Methods	
	
	
Figure	3.2.1:	General	synthesis	scheme	for	derivatives:	(1)	A	(1.0	eq.),	CH3NH2/CH3OH	(33%	
CH3NH2	by	wt.,	10	eq.);	(2)	B	(1.0	eq.),	Fmoc-Leu-OH	(2.0	eq.),	DIC	(2.0	eq.),	Oxyma	Pure	(2.0	
eq.),	N,N-Diisopropylethylamine	(2.0	eq.);	(3)	C	(1.0	eq.),	20%	piperidine	in	DMF;	(4)	D	(1.0	eq.),	
chloromethane	sulfonyl	chloride	(7.0	eq.),	N,N-Diisopropylethylamine	(7.0	eq.);	(5)	E	(1.0	eq.),	
potassium	thioacetate	(5.0	eq.),	THF. 
	
The	sulfonyl	ilomastat	derivatives	were	synthesized	following	Figure	2.2.1.	All	compounds	were	
synthesized	using	in	solution	peptide	coupling	and	have	the	same	leucine-tryptophan	
backbone.	The	zinc	binding	group	chloromethane	sulfonyl	chloride	was	added	by	SN2	reaction.	
The	addition	of	thioacetate	to	E,	again,	was	a	SN2	substitution.		
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3.2.1	Chemistry:	General	Procedures	
All	starting	materials	and	reagents	were	commercially	available	and	used	without	further	
purification.	Reactions	were	monitored	via	TLC	with	210	–	270	µm	silica	gel	plates	(EMD	
Chemicals	Inc.,	5715-7)	using	UV	light	and	potassium	permanganate.	Flash	column	
chromatography	was	performed	using	230	–	400	mesh	ultra	pure	silica	gel,	with	a	pore	
diameter	of	60	Å	(Silicycle).	Proton	NMR	of	compound	D	was	performed	on	a	Bruker	
spectrometer	(400	MHz)	with	DMSO-d6	as	the	solvent	(see	appendix).	NanoHPLC-MS/MS	was	
performed,	analysis	of	the	synthesized	compounds	was	done	using	a	QTOF	mass	spectrometer	
(Agilent,	6530)	(appendix).		
 
3.2.1.1	Compound	B:	
0.5062	g	(1.963	mmol)	L-tryptophan	methyl	ester	hydrochloride	(A)	in	2.5	mL	of	MeNH2/MeOH	
(33%	MeNH2	by	wt.)	was	mixed	overnight	under	nitrogen.	Product	was	then	place	on	rotovap	
to	evaporate	MeOH	and	MeNH2	to	yield	L-tryptophan	methyl	amide	(B)	as	a	yellow	oil	(0.4126	
g,	95.6%).	
	
3.2.1.2	Compound	C:	
1.387	g	(3.926	mmol)	Fmoc-Leucine-OH	was	dissolved	in	8	mL	of	1:1	DMF:CH2Cl2	and	mixed	
with	0.61	mL	of	DIC,	0.557	g	of	Oxyma	Pure,	and	0.70	mL	of	N,N-Diisopropylethylamine	under	
nitrogen	at	room	temperature	for	10	minutes.	The	solution	was	then	added	to	0.4126	g	(1.899	
mmol)	compound	B	and	mixed	for	48	hours	under	nitrogen.	Compound	C	was	purified	by	flash	
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column	chromatography	using	2:1	chloroform	to	methanol	as	the	mobile	phase.	Fractions	were	
collected,	and	solvent	evaporated	to	yield	a	yellow-orange	oil	(0.8126	g,	77.4%).	
	
3.2.1.3	Compound	D	(Leu-Trp):		
0.08126	g	(0.147	mmol)	Fmoc-Leucine-Tryptophan	was	mixed	with	4	mL	of	20%	piperidine	in	
DMF	for	two	hours.	Compound	D	was	purified	by	the	same	flash	column	chromatography	as	
Compound	C.	Fractions	were	collected,	and	solvent	evaporated	to	yield	a	yellow-orange	oil	
(0.041	g,	83.9%,	LC-MS/MS	m/z:	331.2177	(M+H),	NMR	400	MHz:	~11	ppm	H	on	N	of	Trp	five	
carbon	ring,	~7	ppm	Trp	aromatic	H,	~1	ppm	H	on	methyl	groups	of	Leu).	
	
3.2.1.4	Compound	E	(AP-1):	
0.78	mL	(8.627	mmol)	of	chloromethane	sulfonyl	chloride	was	added	to	0.4097	g	(1.23	mmol)	
of	Compound	D.	1.55	mL	(8.627	mmol)	of	N,N-Diisopropylethylamine	was	then	added	and	the	
mixture	was	refluxed	under	nitrogen	overnight.	Compound	E	was	purified	by	the	same	flash	
chromatography	method	as	the	previous	compounds.	Fractions	were	collected,	and	solvent	
evaporated	to	yield	a	reddish-orange	oil	(0.5154	g,	94.5%,	LC-MS/MS	m/z:	443.1669	(M+H)).	
	
3.2.1.5	Compound	F	(AP-2):		
0.09855	g	(0.8629	mmol)	potassium	thioacetate	was	mixed	with	8	mL	of	THF	until	dissolved.	
The	solution	was	then	added	to	0.0764	g	(0.1726	mmol)	of	Compound	E	and	refluxed	under	
nitrogen	for	48	hours.	Purification	of	Compound	F	was	performed	by	the	same	flash	column	
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chromatography	as	previous	compounds.	Fractions	were	collected,	and	solvent	evaporated	to	
yield	a	reddish-brown	oil	(0.0443	g,	54.9%,	LC-MS/MS	m/z:	467.1723	(M+H)).	
	
3.2.2	In	Silico	Molecular	Docking	
First	the	MMP3	protein	(PDB:4G9L),	co-crystalized	with	the	inhibitor	NNGH,	was	prepared	for	
the	molecular	dynamics	simulation	by	deleting	alpha	chains,	adding	protons,	and	ensuring	that	
the	protonation	states	of	the	crystalline	structure	were	correct.	MMP3	(PDB:4G9L)	was	
solvated	using	periodic	boundary	conditions	with	NaCl	counter	ions.	Amber10:	EHT	was	the	
forcefield	used	to	minimize	energy	with	rigid	water	constraints	to	an	optimization	gradient	of	
0.1	kcal/mol	Å2.		
	 The	molecular	dynamics	simulation	was	performed	using	the	NPA	algorithm	and	
Amber10:	EHT	forcefield.	In	the	simulation,	the	system	was	heated	up	to	310K	for	220ps,	then	
ran	at	a	constant	temperature	of	310K	for	800ps	to	allow	for	the	protein	to	anneal.	During	the	
simulation,	the	phase	space	was	sampled	every	0.5ps,	all	light	bonds	constrained	and	rigid	
water	molecules	used	with	the	time	step	being	2	fs.	Compounds	were	docked	using	the	last	
trajectory.		
	 MMP-3	active	site	was	set	to	the	entire	protein	as	well	as	the	catalytic	zinc	ion	and	
active	site	bound	water	molecule.	Compounds	with	an	acidic	proton	were	deprotonated	and	
charges	fixed	before	compounds	were	docked.	Generation	of	random	poses	for	each	
compound	was	performed	using	the	proxy	triangle	algorithm.	Each	conformer	was	scored	using	
the	London	dG	scoring	function,	with	the	top	thirty	poses	rescored	using	induced	fit	refinement	
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algorithm.	Top	five	poses	were	ranked	by	the	Gibbs	binding	energy,	scored	using	the	
Generalized-Born	Volume	Integral/Weighted	Surface	Area	(GBVI/WSA)	algorithm.		
	
3.2.3	NFF-3	Fluorescence	Assay	
Cells	were	plated	on	a	20cm	plate	and	grown	to	confluence	(3-4	days).	The	plate	was	washed	
twice	with	PBS,	once	with	serum	free	phenol	red	free	media	and	conditioned	with	15	mL	of	
serum	free	phenol	red	free	media	for	24	hours.	After	24	hours,	the	conditioned	media	was	
collected	and	1400	µL	portioned	out	into	9	Eppendorf	tubes.	Inhibitors	were	added	resulting	in	
a	final	concentration	of	50	µL	or	100	µL.	Each	experimental	condition	had	its	own	control	
condition.	Using	a	96	well	plate	15	µL	of	distilled	water	were	added	to	the	control	wells	and	15	
µL	of	100	µM	NFF-3	were	added	to	the	experimental	well.	Then	300	µL	of	the	conditioned	
media	with	inhibitors	were	added	to	the	control	and	experimental	wells,	resulting	in	an	overall	
concentration	of	4.76	µM	NFF-3.	The	excitation	wavelength	of	the	spectrometer	was	set	to	325	
nm	while	the	emission	was	set	to	393	nm.	Fluorescence	was	measured	every	ten	minutes	over	
the	course	of	six	hours,	with	the	plate	shaking	for	15	seconds	before	each	reading.	The	
experiment	was	conducted	at	37°C.	
	
3.3	Results	&	Discussion	
3.3.1	Synthesis	of	Ilomastat	Derivatives	
	Sulfonyl	ilomastat	derivatives	were	designed	based	on	the	backbone	of	ilomastat,	but	using	a	
sulfonyl	ZBG	in	place	of	hydroxamic	acid.	Of	the	seven	compounds	proposed	(Figure	3.3.1),	the	
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leucine-tryptophan	backbone	was	the	first	synthesized.	AP-1	was	produced	by	coupling	the	
backbone	with	chloromethane	sulfonyl	chloride.	Finally,	AP-2	was	synthesized	using	an	SN2	
substitution	with	thioacetate.	Synthesis	and	evaluation	of	MMP	inhibitors	were	limited	to	3	
compounds.			
	
Figure	3.3.1:	Proposed	ilomastat	derivatives.	Compounds	include	the	leucine-tryptophan	
backbone,	and	ilomastat	(commercially	available).	Below	each	compound	is	the	binding	energy	
score	calculated	for	the	MMP-3	active	site	using	the	MOE	software.		
Ilomastat and	Ilomastat Derivatives	for	Modelling
Leu-Trp Ilomastat AP-1
AP-2 AP-3 AP-4
AP-5 AP-6 AP-7
-8.0	kcal/mol -12.1	kcal/mol -7.7	kcal/mol
-8.5	kcal/mol -11.0	kcal/mol -9.6	kcal/mol
-9.3	kcal/mol -12.3	kcal/mol -11.6	kcal/mol
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Figure	3.3.2:	Interaction	diagrams	for	ilomastat,	Leu-Trp,	AP-1,	and	AP-2.	Shown	are	the	most	
favourable	interaction	diagrams	for	synthesized	compounds	leucine-tryptophan	backbone,	AP-
1,	AP-2,	and	ilomastat.		
	
Ilomastat Leu-Trp
AP-1 AP-2
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Figure	3.3.3:	Interaction	diagrams	for	AP-3,	AP-4,	AP-5,	AP-6,	and	AP-7.	Shown	are	the	most	
favourable	interaction	diagrams	for	proposed	compounds	AP-3,	AP-4,	AP-5,	AP-6,	and	AP-7.	
	
AP-3 AP-4
AP-5 AP-6
AP-7
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3.3.2	Molecular	Docking	of	Ilomastat	Derivatives		
All	proposed	compounds	(Figure	3.3.1)	were	subjected	to	molecular	docking	to	predict	their	
interaction	with	the	MMP-3	active	site.	In	the	MOE	software,	assigned	overall	best	scores	
(binding	energy),	the	most	negative,	based	on	interactions	such	as	ionic	bonds,	hydrogen	
bonds,	and	hydrophobic	interactions.	When	bonds	are	formed,	energy	is	released,	resulting	in	a	
decrease	in	entropy,	for	a	more	thermodynamically	stable	system.	Thus,	lower	binding	energy	
is	a	predictor	for	the	stability	of	the	interaction	between	the	compound	and	active	site	of	MMP-
3.	Furthermore,	all	compounds	examined	here	demonstrated	ligand	exposure,	indicating	each	
compound	had	regions	that	did	not	interact	with	the	active	site	of	MMP-3	(Figure	3.3.2	and	
Figure	3.3.3).	As	competitive	inhibitors,	a	reduction	in	ligand	exposure	was	used	as	predictive	
measure	that	the	compound	would	be	a	better	inhibitor	of	MMP-3.	Majority	of	the	compounds	
display	the	indole	ring	of	tryptophan	with	an	arene-H	interaction	to	the	amino	acids	of	the	
active	site,	which	would	stabilize	the	compound.	However,	the	indole	ring	also	is	a	destabilizing	
factor	in	most	of	the	proposed	compounds	due	to	ligand	exposure.		
	 All	proposed	compounds	have	the	same	leucine-tryptophan	backbone,	but	with	varying	
ZBGs.	As	expected,	Leu-Trp,	which	lacks	a	ZBG,	has	no	interaction	with	the	active	site	zinc	ion.	
The	backbone	does	have	favourable	interactions	with	the	active	site,	giving	Leu-Trp	a	higher	
score	than	AP-1.	The	ZBG	of	both	AP-1	and	AP-2	is	predicted	not	bind	to	the	zinc	ion,	but	the	
ketone	portion	of	the	amino	acid	backbone	does	coordinate	to	the	zinc,	resulting	in	a	lower	
score	than	the	backbone	and	ilomastat.		
It	is	expected	that	ZBGs	that	form	a	bidentate	interaction	and	more	bonds	with	the	zinc	
ion	would	result	in	a	lower	binding	energy,	and	thus	would	be	a	higher	scoring	candidate	for	
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catalytic	inhibition.	An	increase	in	bonds,	leads	to	a	decrease	in	entropy	in	the	system,	and	an	
overall	more	stability.	Two	of	the	top	scoring	compounds,	ilomastat	and	AP-7,	are	both	
predicted	to	have	bidentate	binding	to	the	zinc	ion.	However,	AP-4	a	middle	scoring	compound	
also	exhibits	bidentate	binding.	The	remaining	compounds	all	have	monodentate	binding	to	the	
zinc	ion,	including	AP-6,	which	is	the	highest	scoring	proposed	compound.	Considering	that	the	
highest	scoring	compound	has	monodentate	binding,	both	the	chelating	ability	of	the	ZBG	and	
peptide	backbone	have	to	be	considered	when	designing	compounds	to	interact	with	the	MMP-
3	active	site.	
	
3.3.3	NFF-3	of	Ilomastat	and	Synthesized	Compounds	
The	synthesized	compounds	Leu-Trp,	AP-1,	AP-2,	and	ilomastat	were	subjected	to	the	NFF-3	
assay	to	determine	the	biological	inhibition	of	MMP-3.	All	compounds	were	tested	at	a	
concentration	of	50	µM	and	100	µM,	then	compared	to	a	control	of	serum	free	phenol	red	free	
DMEM	media.	For	all	these	compounds,	100	µM	concentration	was	better	at	inhibiting	MMP3	
than	the	50	µM	concentration	(Figure	3.3.4	a).	Synthesized	compounds	and	ilomastat	with	the	
best	predicted	scores	molecular	docking	were:	ilomastat,	AP-2,	Leu-Trp,	and	AP-1.	However,	
NFF-3	data	shows	that	AP-1	performs	better	than	Leu-Trp	at	inhibiting	MMP-3.	While	all	
compounds	do	show	some	inhibition	of	MMP-3,	only	the	100	µM	of	ilomastat	was	found	to	be	
significant	(p	<	0.05).		
	 NFF-3	results	coupled	with	generated	binding	energy	scores	for	each	proposed	
compound	provide	valuable	input	to	predict	biological	compound	performance.	The	change	in	
RFU	value	for	each	compound	was	normalized	to	the	control,	resulting	in	a	value	of	less	than	1.	
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These	normalized	values	were	plotted	against	compound	binding	energy	(Figure	3.3.4).	A	line	of	
best	fit	was	generated	with	an	R2	value	of	0.98997	for	the	inhibitors	at	50	µM	and	0.85178	for	
inhibitors	at	100	µM,	indicating	a	good	correlation	between	the	normalized	RFU	and	binding	
energy	scores.	Normalized	RFU	values	were	calculated	for	the	remaining	proposed	compounds	
that	were	not	synthesized,	and	these	compounds	were	included	on	the	graph	(Figure	3.3.4	d	
and	e).	The	ability	to	predict	the	biological	performance	of	a	compound	based	on	the	generated	
binding	energy	allows	for	more	specific	inhibitor	design.	
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Figure	3.3.4:	Inhibition	of	MMP-3	activity	detected	by	NFF-3	assay.	(a)	NFF-3	assay	over	six	
hours	for	all	synthesized	compounds	and	ilomastat	at	50	µM	and	100	µM	concentration.	(b	&	c)	
Box	and	whisker	plot	of	the	change	in	relative	fluorescence	units	at	six	hours	for	inhibitors	at	a	
concentration	of	50	µM	and	100	µM.	(d	&	e)	The	binding	energy	of	the	synthesized	compounds	
and	ilomastat	were	plotted	versus	the	RFU	values	normalized	to	the	control	at	50	µM	and	100	
µM.	
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3.4	Conclusion	
Seven	ilomastat	derivative	compounds	were	proposed,	MMP-3	active	site	interaction	diagrams	
and	binding	energy	provided	for	each	compound.	Due	to	time	constraints	and	ease	of	synthesis,	
the	leucine-tryptophan	backbone,	AP-1,	and	AP-2	were	synthesized.	All	synthesized	compounds	
were	analyzed	by	mass	spectrometry.	The	NFF-3	assay	was	used	to	determine	the	inhibition	of	
MMP-3	activity	for	ilomastat	and	each	of	the	synthesized	compounds.	Ilomastat	performed	
better	than	the	synthesized	compounds;	Leu-Trp,	AP-1,	and	AP-2,	therefore,	was	chosen	for	
further	biological	studies.		
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Chapter	4:	Biological	Effects	of	MMP-3	Inhibition	by	Ilomastat	
	
4.1	Introduction	
The	activity	of	MMP-3	can	be	inhibited	by	the	peptidomimetic	compound	ilomastat.	However,	
further	studies	into	the	biological	effect	of	MMP-3	inhibition	by	ilomastat	were	required	to	
determine	the	effect	in	vitro.	Different	assays	were	performed	using	C6-13	cells	conditioned	
with	ilomastat	to	further	test	the	effect	on	MMP-3	activity,	the	cytotoxicity	of	ilomastat,	and	
C6-13	migration.	These	assays	included	flow	cytometry	death	assay	to	determine	the	
cytotoxicity	of	the	ilomastat	by	measuring	cells	stained	with	propidium	iodide	(PI);	NFF-3	assay,	
and	zymography,	to	monitor	the	inhibition	of	increasing	ilomastat	concentrations	on	MMP-3	
activity.	Scratch	wound	assay	was	used	to	assess	the	relative	migration	of	the	cells	once	
exposed	to	ilomastat.			
	 Flow	cytometry	is	a	spectroscopy	technique	that	can	be	used	to	distinguish	
characteristics	of	cell	populations.	The	advantage	of	this	technique	is	the	ability	to	analyze	large	
populations	of	cells,	often	thousands	of	cells	per	second.86,87	The	majority	of	flow	cytometers	
use	hydrodynamic	focusing	to	narrow	the	sample	stream	down	to	the	diameter	of	an	average	
cell	by	enclosing	the	sample	stream	in	a	faster	flowing	sheath	stream.86	Since	the	sample	
stream	is	the	diameter	of	a	cell,	the	cell	will	displace	most	of	the	sample	stream	surrounding	it,	
allowing	for	the	fluorophores	associate	with	each	individual	cell	to	be	excited	by	the	laser	beam	
and	be	detected	(Figure	4.1.1).86	The	ability	to	detect	characteristics	of	a	single	cell,	provide	cell	
populations	to	be	grouped	based	upon	defined	characteristics,	such	as	apoptosis.		
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Figure	4.1.1	Flow	cytometry	mechanism.	Sample	of	PI	stained	cells	are	hydrodynamically	
focused	into	a	single	cell	stream	using	sheath	fluid.	As	cells	pass	the	laser,	the	light	beam	is	
disrupted	causing	detectors	to	measure	the	amount	of	forward	and	side	scattered	light.	If	a	cell	
is	stained	with	PI,	PI	will	fluoresce	red	and	will	be	detected	by	the	red	fluorescence	detectors.	
Adapted	from	Abcam	protocol.88		
Sheath	
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Stained	cells
Forward	and	side	
scatter	light	from	all	
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A	change	in	cell	morphology	is	standard	for	the	recognition	of	apoptotic	cells.89	A	defining	
feature	of	apoptotic	cells	is	a	permeable	plasma	membrane	that	is	no	longer	intact,	allowing	
them	to	be	distinguished	from	alive	cells	via	fluorescent	molecules	such	as	propidium	iodide	
(PI).	PI	is	a	small	molecule	that	intercalates	to	nucleic	acids,	and	thus	cannot	enter	cells	that	
have	an	intact	membrane.90,91	Once	bound	to	nucleic	acids,	PI	can	be	excited	by	wavelengths	
between	400	–	600nm,	and	displays	red	fluorescence	between	600	–	700nm.91	The	ability	to	
distinguish	apoptotic	cells	from	live	cells,	allows	for	the	cytotoxicity	of	a	compound	(in	this	
thesis	ilomastat)	to	be	determined	and	a	concentration	range	to	be	established	for	additional	
assays.	
	 Zymography	is	an	electrophoretic	technique	based	on	SDS-PAGE	in	which	MMP	activity	
can	be	detected.	In	zymography,	enzymatic	substrates	such	as	gelatin,	casein,	and	collagen	are	
co-polymerized	with	the	sodium	dodecyl	sulfate	(SDS)	polyacrylamide	gel.	In	the	
electrophoretic	step	MMPs	are	separated	based	upon	molecular	weight.	In	addition	to	
separating	various	MMPs,	the	electrophoretic	step	also	separates	MMP-TIMP	complexes.92	This	
is	important	to	note	because	TIMPs	are	the	endogenous	inhibitors	of	MMP;	in	order	to	see	
MMP	activity	the	enzymes	must	not	be	inhibited.	Proteins	are	loaded	onto	the	gel	using	a	
standard	denaturing	SDS	loading	buffer.	However,	the	proteins	are	not	boiled	or	treated	with	a	
reducing	agent	such	as	DTT,	in	order	to	limit	the	amount	of	degradation	and	denaturing	of	the	
protein.92	The	SDS	causes	denaturation	and	inactivation	of	MMPs,	although	this	is	reversible,	
and	the	enzymes	partially	renature	and	recover	part	of	the	initial	activity.92,93	Activation	of		pro-
MMPs	is	believed	to	be	due	to	the	cysteine	switch	being	removed	during	denaturation,	
exposing	the	catalytic	zinc	ion.94		
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After	the	electrophoresis,	the	MMPs	are	partially	renatured	by	washing	the	gel	with	a	
non-ionic	detergent	such	as	Triton	X-100,	which	removes	the	SDS	from	the	gel.92	The	gel	is	then	
incubated	overnight	in	buffer	containing	Ca2+,	since	MMPs	are	calcium	dependent.92	The	MMPs	
can	then	degrade	the	substrate	added	to	the	gel.	After	incubation	overnight,	the	gel	is	stained	
with	Coomassie	Blue	and	MMP	activity	is	detected	as	clear	bands.		
	 	
	 Cell	migration	is	essential	to	many	biological	processes	such	as	cell	growth,	
differentiation,	inflammation,	wound	healing,	but	is	also	involved	in	cancer.95	Migration	is	the	
movement	of	individual	cells	or	cell	sheets	from	one	place	to	another,	whereas	invasion	is	the	
migration	of	cells	in	3-dimensional	space	as	they	move	through	the	ECM.95	In	vitro	scratch	
wound	assays	are	a	standard,	simple,	inexpensive	technique	to	measure	collective	cell	
migration	that	somewhat	mimics	in	vivo	cell	migration.96,97	A	cell	free	area,	or	“scratch”,	is	
created	on	the	confluent	cell	monolayer,	the	exposure	to	the	scratch	induces	cells	at	the	edge		
to	migrate	into	the	gap	until	new	cell-cell	connections	are	formed.96,97	The	advantages	of	using	
the	scratch	wound	assay	include:	the	assay	can	be	performed	on	any	plate,	usually	a	multi-well	
plate;	cells	move	in	a	defined	direction;	the	surface	can	be	coated	with	ECM	proteins	of	choice;	
movement	and	morphology	of	cells	can	be	easily	visualized;	it	is	a	simple	and	inexpensive	assay	
to	perform.95	Due	to	its	many	advantages,	the	scratch	wound	assay	is	used	widely	to	study	in	
vitro	migration.		
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4.2	Materials	&	Methods	
4.2.1	Flow	Cytometry	Cell	Death	Assay	
	At	80-90%	confluence,	cells	were	aspirated,	washed	twice	with	PBS	and	treated	with	serum	
free	DMEM	containing	various	concentrations	of	ilomastat	(no	liomastat,	50µM,	100µM,	
200µM)	for	24	hours.	After	24	hours,	conditioned	media	was	collected,	cells	were	removed	
from	the	wells	using	trypsin	and	added	to	the	conditioned	media.	Wells	were	washed	with	PBS	
twice,	with	washes	added	to	the	cells/CM,	and	centrifuged	at	500g	for	5	minutes.	The	
supernant	was	removed	and	the	cell	pellet	was	resuspended	in	2mL	of	PI-FACS	buffer.	Cells	
were	conditioned	in	PI-FACS	buffer	for	15	minutes	at	room	temperature,	in	the	dark,	then	
pelleted	again	at	500g	for	5	minutes.	Cells	were	washed	with	2mL	of	PBS,	pelleted	again,	and	
resuspended	in	4mL	PBS.	For	analysis	1mL	of	the	cell	suspension	was	added	to	2mL	of	PBS.	The	
percentage	of	dead	cells	was	quantified	by	flow	cytometry	(CyAn	ADP,	Beckman	Coulter).		
	 A	second	flow	cytometry	sample	preparation	was	performed	to	limit	the	cell	death	by	
trypsin	in	the	cell	removal	stage	mentioned	above	and	measure	cell	death	over	a	longer	period	
of	time.	Cells	were	grown	to	80-90%	confluence,	washed	twice	with	PBS,	conditioned	with	
serum	free	DMEM,	and	treated	with	the	following	ilomastat	concentrations:	no	ilomastat,	
25µM,	50µM,	75µM,	100µM.	After	72	hours,	the	conditioned	media	was	collected	and	
incubated	in	the	dark	at	37°C	for	15	minutes	in	1mL	of	PI-FACS.	The	cells	were	conditioned	at	
the	same	time	in	2mL	of	PI-FACS	for	15	minutes	at	37°C,	in	the	dark.	After	the	incubation	time,	
cells	were	removed	with	trypsin,	added	to	the	conditioned	media,	wells	were	washed	twice	
with	PBS,	with	the	washes	added	to	the	conditioned	media/cell	suspension.	Cells	were	pelleted	
at	500	x	g	for	5	minutes,	the	supernatant	removed,	resuspended	in	2	mL	of	PBS,	pelleted	again,	
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then	resuspended	in	4mL	of	PBS.	For	analysis	1mL	of	the	cell	suspension	was	added	to	2mL	of	
PBS.	The	percentage	of	dead	cells	was	quantified	by	flow	cytometry	(CyAn	ADP,	Beckman	
Coulter).			
	
4.2.2	NFF-3	Fluorescence	Assay	
Cells	were	plated	on	a	20cm	plate	and	grown	to	confluence	(3-4	days).	The	plate	was	washed	
twice	with	PBS,	once	with	serum-free/phenol-red	free	media	and	conditioned	with	15mL	of	
serum	free	phenol	red	free	media	for	24	hours.	After	24	hours,	the	conditioned	media	was	
collected	and	2500	µL	were	portioned	out	into	five	15	mL	falcon	tubes.	Ilomastat	was	added	to	
have	tubes	with	the	final	following	concentrations:	25	µM,	50	µM,	75	µM,	and	100	µM.	Each	
experimental	condition	had	its	own	control	condition.	Using	a	96	well	plate	15	µL	of	distilled	
water	were	added	to	the	control	wells	and	15	µL	of	100	µM	NFF-3	were	added	to	the	
experimental	well.	Then	300	µL	of	the	conditioned	media	with	inhibitors	were	added	to	the	
control	and	experimental	wells,	resulting	in	an	overall	concentration	of	4.76	µM	NFF-3.	The	
excitation	wavelength	of	the	spectrometer	was	set	to	325nm	while	the	emission	was	set	to	
393nm.	The	fluorescence	was	measured	every	ten	minutes	over	the	course	of	six	hours,	with	
the	plate	shaking	for	15	seconds	before	each	reading.	The	experiment	was	conducted	at	37°C.	
	
4.2.3	Gelatin	Zymography	
Cells	were	plated	on	a	six	well	plate	at	a	concentration	of	200,000	cells	per	well.	Cells	were	
grown	to	confluence	(3-4	days)	and	conditioned	with	serum	free	DMEM.	Ilomastat	was	then	
added	to	the	media	to	a	final	concentration	of	25µM,	50µM,	75µM,	or	100µM.	Cells	were	
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conditioned	for	24	hours.		After	24	hours,	the	conditioned	media	was	collected	and	
immediately	placed	on	ice.	The	conditioned	media	was	concentrated	using	spin	filters,	with	the	
tubes	being	centrifuged	at	4800g	for	12	minutes	in	pre-chilled	rotors.	Protein	concentration	
was	determined	by	BCA	assay.	Protein	samples	were	loaded	on	a	10%	SDS	gel	containing	0.1%	
gelatin	and	ran	at	125V	for	approximately	3	hours.	The	gel	was	then	washed	twice	in	the	
incubation	buffer	with	Triton	X-100	for	a	minimum	of	45	minutes	each.	The	gel	was	washed	for	
10	minutes	in	the	incubation	buffer,	new	incubation	buffer	was	added	and	the	gel	was	placed	in	
a	37°C	incubator	for	20	hours.	After	incubation,	the	gel	was	stained	in	Coomassie	blue	for	1	
hour.	The	gel	was	then	washed	in	destaining	solution	until	bands	appeared.	Photos	were	then	
taken	of	the	gel	and	analyzed	using	ImageJ.	
	
4.2.4	ImageJ	Analysis	
ImageJ	software	was	used	for	both	western	blot	and	zymography	analysis.	Images	in	jpeg	
format	were	uploaded	and	changed	to	an	8-bit	(black	and	white)	image.	Bands	were	selected	
using	the	rectangle	selection	tool,	with	the	rectangle	being	twice	as	high	than	it	is	wide.	The	
first	lane	(band)	was	selected	under	the	“gels”	section	(“select	first	line”)	of	the	“analyze”	tab.	A	
new	rectangle	was	then	generated	and	positioned	over	the	next	band,	this	band	was	then	
selected	under	the	“gels”	section,	“select	next	lane”.	Band	selection	is	continued	until	all	bands	
have	been	selected.	The	lanes	(bands)	can	then	be	plotted	using	the	“plot	lanes”	option	in	the	
“gels”	section,	generating	peaks	for	each	band.	For	zymography	the	peaks	were	inverted	and	
thus	a	straight	line	must	be	drawn	from	the	baseline	to	baseline	to	enclose	the	peak.	Once	
peaks	are	enclosed	the	wand	tool	is	used	to	select	inside	the	peak	and	the	area	of	the	peak	is	
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generated	by	selecting	“label	peaks”	from	the	“gels”	section.	The	area	of	the	peak,	and	thus	the	
area	of	the	band	corresponds	to	the	relative	amount	of	MMP-3	present.		
	
4.2.5	Scratch	Wound	Assay	
Cells	were	plated	on	a	six	well	plate	at	a	concentration	of	200,000	cells	per	well.	Cells	were	
grown	to	confluence	(3-4	days),	then	a	1	mm	scratch	was	made	through	the	center	of	the	wells	
using	a	P1000	pipette	tip.	Cells	were	then	washed	twice	with	PBS,	once	with	low	glucose	(serum	
free	phenol	red	free	media)	or	high	glucose	(serum	free)	media	and	conditioned	with	1.5mL	of	
low	glucose	or	high	glucose	media.	Ilomastat	was	then	added	to	the	media	to	have	a	final	
concentration	of	25	µM,	50	µM,	75	µM,	or	100	µM.	Images	of	the	scratch	were	taken	(t=0)	
using	the	Zeiss	Axio	Zoom.V16	microscope	at	68x	magnification	and	78%	amplification,	using	
the	Zen	Blue	Lite	software.	Images	were	taken	again	at	t=24	hours	and	t=48	hours.	Images	were	
then	analyzed	using	ImageJ,	the	20	furthest	moving	cells	were	measured	and	the	relative	
migration	was	calculated.		
4.3	Results	&	Discussion	
4.3.1	Flow	Cytometry	Cell	Death	Assay	
Ilomastat	cytotoxicity	was	tested	to	determine	ilomastat	concentrations	for	further	biological	
studies	such	as	NFF-3,	zymography,	and	scratch	wound.	Initially,	ilomastat	concentrations	of	50	
µM,	100	µM,	and	200	µM	were	used	to	measure	the	amount	of	cell	death	after	24	hours	of	
conditioning.	Cells	were	then	removed	and	stained	with	propidium	iodide.	More	PI	uptake	
results	in	higher	PI	fluorescence,	which	is	detected	using	PE	CD38Log,	a	red	fluorescence	
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detector.	PI	fluorescence	was	measured	against	the	side	scatter	of	the	cells	(Figure	4.3.1	a	&	b).	
PI	fluorescence	versus	the	event	count,	total	number	of	cells,	was	measured	for	additional	cell	
death	data.	Percentage	of	cell	death	was	determined	by	gating	the	two	cell	populations	(Figure	
4.3.1	a	&	b),	apoptotic	cells	will	appear	in	the	top	gate	because	of	the	higher	PI	fluorescence,	
whereas	alive	cells	will	appear	in	the	bottom	gate.	The	percentage	of	cell	death	for	each	
condition	can	be	seen	in	Figure	4.3.1	c.	Amount	of	cell	death	measured	for	each	condition	is	
high	for	a	24-hour	conditioning	period.	Cell	death	normalized	to	the	control	gives	more	
reasonable	values,	although	the	200	µM	treatment	still	has	considerable	cell	death.		
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Figure	4.3.1:	Cytotoxicity	of	ilomastat	after	24	hours.	(a	&	b)	After	conditioning	for	24	hours,	
cells	stained	with	propidium	iodide	were	measured	using	flow	cytometry,	50	µM	and	200	µM.	
(c)	Cell	death	after	24	hours.	(d)	Cell	death	normalized	to	the	no	ilomastat	treatment.		
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The	amount	of	cell	death	occurring	in	this	procedure	may	be	due	to	the	sample	prep	itself.	C6-
13	are	very	adherent	cells,	and	thus	can	be	more	difficult	to	detach	from	the	plate.	During	
incubation	with	trypsin	to	detach	cells,	additional	cell	death	may	have	occurred	if	the	cells	were	
incubated	for	too	long,	adding	to	the	cell	death	from	ilomastat.	A	substantial	amount	of	cell	
death	occurs	in	the	control	sample	(Figure	4.3.1	c),	indicating	that	this	cell	death	is	due	to	
natural	processes	or	sample	preparation.	The	control	sample	does	contain	DMSO,	but	DMSO	
contribution	to	cell	death	can	be	ruled	out	because	concentrations	below	1%	are	safe	for	most	
cell	lines.	Therefore,	the	majority	of	the	cell	death	must	be	due	to	sample	preparation,	
specifically	the	incubation	of	trypsin.	In	addition,	visually	there	was	little	to	no	cell	death	in	
these	samples.		
	 A	secondary	protocol	was	tested	using	a	gentler	cell	approach	and	staining	the	cells	
before	removal	from	the	plate.	Experimental	time	period	was	changed	from	24	hours	to	72	
hours	because	little	cell	death	should	occur	after	72	hours	and	the	maximum	time	point	in	the	
scratch	wound	assay	would	be	48	hours.	Concentration	of	ilomastat	used	was	changed	to	25	
µM,	50	µM,	75	µM,	and	100	µM.	Cell	death	from	applying	200	µM	in	the	first	protocol	was	
relatively	high	and	it	is	not	recommended	to	use	concentrations	above	100	µM79.	Using	the	
secondary	protocol,	there	was	a	significant	decrease	in	cell	death	across	all	ilomastat	
concentrations	and	control.	All	conditions	have	less	than	1%	cell	death	(Figure	4.3.2	b),	
signifying	that	at	these	concentrations,	ilomastat	is	not	cytotoxic	over	a	72-hour	time	period.	
Ilomastat	concentrations	25	µM,	50	µM,	75	µM,	and	100	µM	was	used	in	further	biological	
studies.		
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Figure	4.3.2:	Cytotoxicity	of	ilomastat	after	72	hours.	(a)	Flow	cytometry	of	red	fluorescence	
detector	PECD38	Log	versus	side	scatter	for	each	experimental	condition.	(b)	Cell	death	after	72	
hours	for	each	condition.		
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4.3.2	NFF-3	Fluorescence	Assay	
Inhibition	of	MMP-3	by	ilomastat	was	tested	using	the	NFF-3	assay	(same	as	in	chapter	2	&	3).	
As	determined	by	the	flow	cytometry	experiment,	ilomastat	concentrations	used	were	25	µM,	
50	µM,	75	µM,	and	100	µM.	A	significant	difference	occurs	between	the	control	and	all	four	of	
the	ilomastat	treatments,	with	significance	increasing	as	the	ilomastat	concentration	increases.	
Thus,	all	treatment	concentrations	had	an	inhibitory	effect	on	MMP-3.			
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Figure	4.3.3:	Inhibition	of	MMP-3	activity	by	varying	ilomastat	concentrations.	(a)	Change	in	
RFU	for	each	concentration	of	ilomastat.	(b)	Normalized	RFU	of	all	biological	replicates,	showing	
significance	for	each	condition.	(c)	T-test	comparison	of	all	biological	replicates	showing	
statistical	significance	for	all	replicates.	
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4.3.3	Gelatin	Zymography	
A	further	insight	into	MMP-3	activity	was	performed	using	gelatin	zymography.	As	mentioned	in	
Chapter	2,	gelatin	is	a	substrate	of	MMP-3,	thus	gelatin	zymography	was	performed	to	monitor	
the	effect	of	MMP-3	inhibition	by	ilomastat	on	a	natural	substrate	of	MMP-3.		MMP-3	has	a	
molecular	weight	of	54	kDa	and	can	be	seen	just	below	the	60	kDa	protein	marker	(Figure	
4.3.4a).	As	can	be	seen	in	Figure	4.3.4a,	increases	in	ilomastat	concentration	result	in	decrease	
of	thickness	and	visibility	of	MMP-3	bands,	indicating	that	less	gelatin	is	being	degraded.	The	
decrease	in	degradation	of	gelatin	is	noteworthy,	because	it	signifies	that	MMP-3	inhibition	
does	have	an	effect	on	degradation	of	its	substrates	and,	thus,	may	have	an	effect	on	MMP-3	
involvement	in	migration.	All	the	concentrations	of	ilomastat	had	a	significant	effect	on	the	
inhibition	of	MMP-3,	with	the	greatest	significance	occurring	at	the	highest	concentration	of	
ilomastat.	The	MMP-3	zymography	data	further	supports	the	results	from	the	NFF-3	assay.		
	 In	addition	to	the	MMP-3	results,	multiple	bands	appearred	between	the	90	kDa	and	70	
kDa	protein	markers	indicating	the	presence	of	more	gelatin	degrading	enzymes.	These	bands	
most	likely	belong	to	MMP-9,	which	has	a	molecular	weight	of	92	kDa	in	its	pro-MMP	form	and	
82	kDa	in	its	active	form.	Gelatin	zymography	is	most	commonly	used	for	the	gelatinases	MMP-
9	and	MMP-2.	Pro-MMP-9	is	also	a	substrate	of	MMP-3,	thus	it	is	likely	that	the	additional	
bands	appearing	in	the	zymography	belong	to	MMP-9.	The	bands	of	MMP-9	do	appear	fainter	
as	ilomastat	concentration	increases,	which	could	be	due	to	MMP-3	being	inhibited,	leading	to	
a	reduction	in	the	activation	of	pro-MMP-9	to	MMP-9,	or	simply	ilomastat	inhibiting	MMP-9	
itself.		
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Figure	4.3.4:	Gelatin	zymography	of	varying	ilomastat	treatments.	(a)	MMP-3	appears	just	
below	the	60	kDa	protein	marker.	(b)	Normalized	band	area	of	MMP-3	normalized	to	the	
control,	with	each	ilomastat	treatment	showing	statistical	significance,	and	100	µM	having	the	
highest	significance.			
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4.3.4	Scratch	Wound	Assay	
To	understand	the	effect	of	ilomastat	on	the	migration	of	C613	cells,	the	scratch	wound	assay	
was	performed.	In	these	studies,	C613	cells	were	conditioned	with	either	low	glucose	
(1000mg/L	glucose)	or	high	glucose	(4500mg/L	glucose).	Ilomastat	concentrations	were	set	at	
25µM,	50µM,	75µM,	or	100µM	based	on	the	NFF-3	results.		
The	relative	migration	of	the	top	20	most	migratory	cells	were	taken	for	comparison	
from	control	to	ilomastat	treatments	(Figure	4.3.5	-	4.3.8).	There	was	an	insignificant	decrease	
in	migration	from	the	control	to	the	treatments,	but	the	decrease	in	migration	was	not	
dependent	on	the	concentration	of	ilomastat.	In	addition,	corresponding	to	the	literature98,99,	
cells	conditioned	with	low	glucose	media	had	a	higher	relative	migration	in	comparison	to	cells	
conditioned	with	high	glucose	media	(Figure	4.3.9).		
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Figure	4.3.9:	Relative	migration	of	each	ilomastat	treatment	for	low	glucose	and	high	glucose	
media	at	24	and	48	hours.	
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The	fact	that	there	was	no	change	between	the	control	and	experimental	conditions	in	the	
migration	of	cells	in	the	scratch	wound	assay	may	be	attributed	to	the	disadvantages	to	the	
assay	itself.	Some	of	the	disadvantages	of	the	scratch	wound	assay	include:	the	size	and	shape	
of	the	scratch	can	vary	from	well	to	well;	monolayer	confluence	from	control	to	experimental	
conditions	may	not	be	the	same;	the	ECM	and	ECM	proteins	can	be	damaged	by	the	scratching	
of	the	monolayer.95	In	addition,	the	edges	of	the	scratch	often	retract	indicating	that	cells	on	
the	edge	of	the	scratch	may	have	lost	their	original	morphology	and	function	due	to	the	
physical	stress	from	the	scratch.100		
	 As	mentioned	above	the	scratch	wound	assay	has	many	disadvantages	that	may	
contribute	to	the	inconsistency	in	results.	This	may	be	overcome	by	increasing	the	number	of	
biological	replicates	or	trying	to	further	minimize	any	variation	that	may	occur	from	well	to	
well.	Another	factor	that	may	have	contributed	to	non-significant	results,	is	the	fact	that	
ilomastat	is	an	MMP	inhibitor,	and	MMPs	aid	migration	in	cleaving	the	ECM.	If	the	ECM	
produced	by	the	cells	was	damaged	due	to	the	scratch,	there	would	be	no	mechanical	
resistance	preventing	the	cells	from	migrating,	therefore	the	addition	of	ilomastat	would	be	
ineffective.	This	could	be	overcome	by	adding	artificial	ECM,	such	as	matrigel	to	the	wells	
providing	the	mechanical	resistance.		
Another	assay	to	try	would	be	the	tumor	spheroid	invasion	assay.	In	this	assay	cells	are	
grown	in	vitro	in	a	low-adhesion,	round	bottom	well	to	promote	the	formation	of	spheroids.	
Matrigel	is	added	and	the	cell	migration	out	of	the	tumor	spheroid.	This	assay	is	a	better	
representation	of	how	migration	away	from	a	tumor	occurs	and	may	be	a	better	assay	to	
investigate	MMP-3	in	this	cell	system. 
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In	a	study	by	Yan	et	al.	2016,	it	was	shown	that	GBM	cells	treated	with	ilomastat	may	be	able	to	
overcome	the	loss	of	protease-dependent	migration	by	switching	to	an	amoeboid-like	
migration.	Ilomastat	caused	the	activation	of	RhoA/ROCK/MLC	signal	causing	mesenchymal-
amoeboid	transition	in	the	cells,	inducing	amoeboid-type	cell	migration.101	The	combination	of	
ilomastat	and	a	RhoA/Rho	kinase	inhibitor	decreased	the	invasiveness	of	cells.101	Therefore,	a	
combination	of	inhibitors	may	be	needed	to	have	a	beneficial	effect	on	migration	and	invasion.			
4.4	Conclusion	
Ilomastat	was	used	for	further	biological	studies	on	the	inhibition	of	MMP-3.	First,	the	
cytotoxicity	of	ilomastat	was	determined	using	propidium	iodide	flow	cytometry.	From	the	flow	
cytometry	data,	it	was	determined	that	the	highest	concentration	of	ilomastat	for	biological	
assays	would	be	100	µM.	The	NFF-3	assay	was	then	performed	to	see	if	there	was	a	correlation	
between	increasing	ilomastat	concentration	and	the	inhibition	of	MMP-3.	Gelatin	zymography	
data	further	support	the	NFF-3	data	in	that	increasing	ilomastat	concentration	does	in	fact	lead	
to	an	inhibition	of	MMP-3	and	a	decrease	in	its	activity.	Finally,	scratch	wound	assays	were	
performed	to	monitor	the	effect	of	MMP-3	inhibition	on	migration.	While	no	significant	change	
was	noticed	in	the	scratch	wound	assays	performed,	it	cannot	conclusively	be	said	that	MMP-3	
does	not	play	a	role	in	migration,	further	investigation	into	this	area	is	needed.	
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Chapter	5:	Overview	of	Research	and	Future	Directions	
	
5.1	Overview	of	Research	
The	overall	objective	of	this	thesis	was	to	analyze	the	enzymatic	inhibition	of	MMP-3	through	
the	use	of	peptidomimetic	inhibitors.	The	initial	step	of	this	thesis	was	to	further	confirm	the	
upregulated	expression	of	MMP-3	in	C6-13	cells	through	my	own	mass	spectrometry	secretome	
experiment	and	Western	blot	analysis.	Both	experiments	showed	an	increased	expression	of	
MMP-3	in	the	C6-13	cells	over	the	C6	cells.	Knowing	that	the	expression	of	MMP-3	is	
upregulated,	the	next	step	was	to	determine	if	the	activity	of	MMP-3	is	correlated	to	expression	
through	the	use	of	the	fluorescent	NFF-3	assay.	It	was	found	that	in	addition	to	the	expression	
of	MMP-3	being	upregulated	so	is	the	activity.		
	 The	third	chapter	of	the	thesis	focused	on	the	design,	synthesis,	and	molecular	docking	
of	peptidomimetic	MMP-3	inhibitors.	Inhibitors	were	proposed	and	synthesized	based	on	ease	
of	synthesis.	Leu-Trp,	AP-1,	AP-2,	were	synthesized	and	analyzed	by	mass	spectrometry.	AP-3	
was	in	the	process	of	being	synethsized	but	was	not	identified	by	mass	spectrometry,	thus	
needs	further	work.	All	proposed	inhibitors	and	ilomastat	were	docked	into	the	actives	site	of	
MMP-3	using	in	silico	molecular	docking.	The	top	scoring	inhibitors,	and	thus	the	best	potential	
inhibitors	would	be	AP-6	and	AP-7.	Inhibitory	effect	of	synthesized	compounds	and	ilomastat	
were	tested	using	the	NFF-3	assay.	The	best	performing	compounds	were	AP-6	and	ilomastat.	
However,	since	AP-6	was	has	not	yet	been	synthesized,	ilomastat	was	chosen	for	further	
analysis	on	MMP-3	activity.		
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	 The	final	aim	of	this	thesis	was	to	analyze	how	inhibition	of	MMP-3	effected	its	activity	
and	if	MMP-3	is	involved	with	C6-13	migration.	The	cytotoxicity	of	ilomastat	was	determined	
using	propidium	iodide	flow	cytometry.	From	the	concentrations	of	ilomastat	tested,	it	was	
determined	that	100	µM	would	be	the	highest	concentration	used.		Next	various	ilomastat	
concentrations	were	tested	using	the	NFF-3	assay	to	determine	if	increasing	concentration	led	
to	increasing	MMP-3	inhibition	and	if	there	was	a	maximum	inhibitory	concentration.	It	was	
found	that	all	concentrations	had	a	significant	effect	on	the	inhibition	of	MMP-3,	and	that	the	
significance	increased	as	the	concentration	increase.	There	was	no	maximum	inhibitory	
concentration	determined	for	the	concentrations	used.	Gelatin	zymography	was	used	to	
determine	the	effect	of	MMP-3	inhibition	on	a	natural	substrate	of	MMP-3.	As	with	the	NFF-3	
assay,	increasing	concentration	of	ilomastat,	led	to	an	increase	of	MMP-3	inhibition,	and	
therefore	a	decrease	in	gelatin	degradation.	The	zymography	showed	that	by	inhibiting	MMP-3,	
you	can	reduce	the	degradation	of	its	natural	substrates,	and	may	be	able	to	reduce	its	
contribution	to	migration.		
	 To	test	MMP-3	inhibition	on	migration,	the	scratch	wound	assay	was	used.	Both	high	
glucose	and	low	glucose	DMEM	media	was	used	to	see	if	increased	migration	could	be	induced	
by	using	low	glucose	media.	While	cells	conditioned	in	the	low	glucose	media	did	have	a	higher	
relative	rate	of	migration,	there	was	no	significant	difference	between	the	migration	in	the	
ilomastat	treated	cells	and	the	control.		
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5.2	Future	Research	into	MMP-3	and	the	C6-13	Secretome	
Like	all	cancers,	the	mechanisms	and	pathways	of	GBM	tumors	are	highly	complex.	While	
gaining	more	knowledge	of	these	tumors	is	necessary,	it	is	as	equally	important	to	study	the	
environment	surrounding	the	tumor.	The	tumor	microenvironment	consists	of	cells,	proteins,	
ECM,	and	mechanical	cues	that	protect	the	tumor	from	host	immunity,	provide	therapeutic	
resistance,	promote	growth	and	invasion.102	Thus,	studying	the	tumor	microenvironment,	or	
secretome,	will	provide	better	insight	into	the	mechanism	of	invasion	and	could	provide	better	
therapeutic	targets.	
	
	 An	area	that	needs	further	attention	are	secretome	studies	on	the	C6-13	cells.	Originally	
this	thesis	was	going	to	include	mass	spectrometry	secretome	analysis	comparing	peptide	
cleavages	with	and	without	MMP-3	inhibition,	to	compare	how	these	peptide	cleavages	change	
and	to	get	a	better	understanding	of	the	role	of	MMP-3	in	the	tumor	microenvironment	of	C6-
13	cells.	By	inhibiting	MMP-3	we	would	be	able	to	analyze	the	effects	of	MMP-3	inhibition	not	
only	on	peptide	cleavage,	but	the	proteins	upstream	and	downstream	from	MMP-3	itself.	Being	
able	to	monitor	the	effects	upstream	and	downstream	of	MMP-3	may	offer	alternative	
therapeutic	targets	than	MMP-3.		
			 While	we	did	attempt	TAILS	(terminal	amine	isotopic	labeling	of	substrates)	and	
secretome	studies,	we	were	unable	to	get	a	working	protocol	to	give	consistent	results.	This	
would	be	an	excellent	area	for	future	studies	due	to	some	of	the	ground	work	already	being	in	
place.	Better	understanding	of	the	role	of	MMP-3	in	the	tumor	microenvironment	of	C6-13	cells	
may	provide	insight	into	new	therapeutics	and	MMP-3	inhibitors.		
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The	inhibitors	synthesized	in	this	thesis	did	not	perform	better	than	the	commercially	
available	ilomastat.	However,	the	proposed	compound	AP-6	did	have	a	better	score	than	
ilomastat	in	the	molecular	docking	simulations	and	was	projected	to	have	better	MMP-3	
inhibition	by	the	NFF-3	assay.	Thus,	it	may	be	worthwhile	to	synthesize	AP-6	to	determine	if	it	
does	outperform	ilomastat.	In	addition,	it	would	be	worthwhile	to	do	more	molecular	docking	
simulations,	varying	both	the	zinc	binding	group	and	the	peptide	backbone,	to	determine	the	
zinc	binding	group	with	the	best	chealting	ability	and	the	backbone	that	fits	the	best	in	the	
MMP-3	subpockets.		
While	very	few	MMP-3	specific	inhibitors	exist,	a	study	including	a	reversed	4-biaryl	
piperidine	sulfonamide	core,	located	next	to	the	ZBG,	bound	specifically	to	the	S1’	subsite	of	
MMP-3.56	The	inclusion	of	the	sulfonamide	core	may	help	direct	the	remainder	of	the	backbone	
into	additional	subpockets.	When	designing	future	backbones	of	MMP-3	inhibitors	it	will	be	
important	to	take	into	consideration	the	amino	acids	that	fit	most	favorably	into	each	
subpocket.	From	Eckhard	et	al.	the	most	favorable	amino	acids	for	the	MMP-3	active	site	are	
shown	in	Figure	5.2.1.	
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Figure	5.2.1:	MMP-3	active	site	with	amino	acid	preference	for	each	subsite.	Adapted	from	
Eckhard	et	al.	2016.103	
	
This	thesis	showed	that	MMP-3	inhibition	is	capable	in	C6-13	cells,	but	we	were	unable	to	
demonstrate	whether	MMP-3	inhibition	has	an	impact	on	migration.	Further	studies	into	MMP-
3	inhibition	on	migration	and	invasion	are	needed.	Such	studies	could	include	a	scratch	wound	
assay	incorporating	Matrigel,	3D	spheroid	invasion	assay,	or	a	transwell	assay,	all	of	which	
would	be	better	representations	of	migration	and	invasion	due	to	the	synthetic	ECM	
environment.		The	3D	spheroid	assay	and	transwell	assay	are	both	better	in	vitro	models	to	
simulate	the	process	that	occurs	in	vivo.		
Studies	on	MMP-3	should	be	continued	because	MMP-3	upregulation	is	not	only	seen	in	
the	C6-13	GBM	cells.	MMP-3	upregulation	also	occurs	in	breast,	gastric,	and	lung	cancer,	
corresponding	to	increased	cancer	progression	and	metastasis.104	Further	understanding	of	
MMP-3,	the	pathways	upstream	and	downstream,	may	offer	insight	into	the	mechanism	of	
cancer	while	providing	new	avenues	for	development	of	therapeutics	to	inhibit	the	disease.	
MMP-3	Active	Site
P3 P2 P1 Zn2+ P1’ P2’ P3’
P A N/E L/I/V I/V G/A P/D
A	– alanine L	– leucine	
D	– aspartic	acid N	– asparagine	
E	– glutamic	acid P	– proline	
G	– glycine V	– valine	
I	– isoleucine	
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Appendix	2	
	
Appendix	2:	Monoisotopic	(M)	mass,	theroretical	M+H	mass,	and	the	experimental	M+H	
determined	by	LC-MS/MS	for	the	compounds	Leu-Trp,	AP-1,	and	AP-2.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Compound Monoisotopic	(M)	
Mass
Theoretical M+H Experimental	
M+H
330.2056 331.2056 331.2177
442.1442 443.1442 443.1669
466.1708 467.1708 467.1723
AP-1
AP-2
Leu-Trp
	 104	
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[M+H]+:	443.1442
AP-1
	 105	
	
Appendix	3:	Mass	spectrometry	results	for	Leu-Trp,	AP-1,	and	AP-2.	Experimental	M+H	values	
located	under	each	spectra	correspond	to	the	peaks	determined	by	mass	spectrometry	for	each	
compound.	
	
	
	
	
	
	
	
	
	
	
	
	
	
